Amarantus BioScience (AMBS) 10-K/A 22 Apr 14 2013 FY Annual report (amended) Financial data

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
	Dec. 31, 2013	Apr. 18, 2014	Jun. 30, 2013
Document Information [Line Items]	'	'	'
Entity Registrant Name	'Amarantus Bioscience Holdings, Inc.	'	'
Entity Central Index Key	'0001424812	'	'
Current Fiscal Year End Date	'--12-31	'	'
Entity Filer Category	'Smaller Reporting Company	'	'
Trading Symbol	'AMBSE	'	'
Entity Common Stock, Shares Outstanding	'	715,072,890	'
Document Type	'10-K	'	'
Amendment Flag	'false	'	'
Document Period End Date	31-Dec-13	'	'
Document Fiscal Period Focus	'FY	'	'
Document Fiscal Year Focus	'2013	'	'
Entity Well-known Seasoned Issuer	'No	'	'
Entity Voluntary Filers	'No	'	'
Entity Current Reporting Status	'Yes	'	'
Entity Public Float	'	'	$13,212,917

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2013	Dec. 31, 2012
Current assets:	'	'
Cash and cash equivalents	$1,032,634	$157,174
Prepaid expenses and other current assets	215,186	520,620
Total current assets	1,247,820	677,794
Intangible assets	611,094	532,143
Total assets	1,858,914	1,209,937
Current liabilities:	'	'
Accounts payable	971,199	2,596,848
Accrued liabilities	292,395	18,746
Accrued interest	112,124	109,861
Related party liabilities	247,967	243,525
Convertible notes payable	0	740,000
Warrant liability	0	232,988
8% Senior convertible debentures	931,942	0
Convertible promissory notes	124,393	768,892
Derivative liability	5,859,170	26,893
Total current liabilities	8,539,190	4,737,753
Total liabilities	8,539,190	4,737,753
Commitments and contingencies	'	'
Stockholders’ equity (deficit):	'	'
Common stock, $0.001 par value - 1,000,000,000 shares authorized at December 31, 2013 and 2012, respectively; 574,171,945 and 342,516,931 shares issued and outstanding at December 31, 2013 and 2012, respectively	574,172	342,517
Additional paid-in capital	18,938,039	7,991,465
Deficit accumulated during the development stage	-27,032,131	-11,862,048
Total stockholders’ equity (deficit)	-7,519,170	-3,527,816
Total liabilities and stockholders’ equity (deficit)	1,858,914	1,209,937
Series A Convertible Preferred Stock [Member]	'	'
Stockholders’ equity (deficit):	'	'
Preferred Stock, Value, Issued	0	250
Series B Convertible Preferred Stock [Member]	'	'
Stockholders’ equity (deficit):	'	'
Preferred Stock, Value, Issued	0	0
Series C Convertible Preferred Stock [Member]	'	'
Stockholders’ equity (deficit):	'	'
Preferred Stock, Value, Issued	750	0
Series D Convertible Preferred Stock [Member]	'	'
Stockholders’ equity (deficit):	'	'
Preferred Stock, Value, Issued	$838,894	$0

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Common Stock, Par or Stated Value Per Share	$0.00	$0.00
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000
Common Stock, Shares Issued	574,171,945	342,516,931
Common Stock, Shares Outstanding	574,171,945	342,516,931
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Series D Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$1,000	$1,000
Preferred Stock, Shares Authorized	1,300	1,300
Preferred Stock, Shares Issued	1,299.33	0
Preferred Stock, Shares Outstanding	1,299.33	0
Preferred Stock Shares, Designated	1,300	1,300
Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Series A Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Issued	0	250,000
Preferred Stock, Shares Outstanding	0	250,000
Preferred Stock Shares, Designated	250,000	250,000
Series B Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Preferred Stock Shares, Designated	2,500,000	2,500,000
Series C Convertible Preferred Stock [Member]	'	'
Preferred Stock, Par Value	$0.00	$0.00
Preferred Stock, Shares Issued	750,000	0
Preferred Stock, Shares Outstanding	750,000	0
Preferred Stock Shares, Designated	750,000	750,000

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended		72 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Net Revenues	$0	$0	$415,996
Operating Expenses:	'	'	'
Research and development	2,088,992	583,869	4,278,647
General and administrative	3,622,142	3,506,473	11,573,062
Total operating expenses	5,711,134	4,090,342	15,851,709
Loss from operations	-5,711,134	-4,090,342	-15,435,713
Other income (expense):	'	'	'
Interest expense	-2,630,914	-1,518,420	-5,360,513
Loss on issuance of common stock	-352,096	0	-352,096
Loss on issuance of debt	-6,708,728	0	-6,708,728
Other income (expense)	0	-11,862	75,827
Change in fair value of warrants and derivative liabilities	271,191	485,006	1,153,365
Total other income (expense)	-9,420,547	-1,045,276	-11,192,145
Net loss	-15,131,681	-5,135,618	-26,627,858
Preferred stock dividend	38,402	0	38,402
Net loss applicable to common stockholders	($15,170,083)	($5,135,618)	($26,666,260)
Per share net loss applicable to common stockholders’:	'	'	'
Basic and fully diluted (in dollars per share)	($0.03)	($0.04)	'
Weighted average shares used in computing basic loss per share:	'	'	'
Basic and fully diluted (in shares)	450,931,510	140,710,454	'

Consolidated_Statements_of_Sto

Consolidated Statements of Stockholders' Equity (Deficit) (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Convertible Preferred Stock [Member]
Balances at Jan. 13, 2008	$0	$0	$0	$0	$0
Balances (in shares) at Jan. 13, 2008	'	0	'	'	0
Issuance of common stock in December 2006 at $0.001 per share in exchange for cash or services	4,020	4,020	0	0	0
Issuance of common stock in December 2006 at $0.001 per share in exchange for cash or services (in shares)	'	4,020,000	'	'	0
Sale of warrant to investor	35	0	35	0	0
Dividend to founder for assumption of debts	-365,870	0	0	-365,870	0
Net loss	-406,706	0	0	-406,706	0
Balances at Dec. 31, 2008	-768,521	4,020	35	-772,576	0
Balances (in shares) at Dec. 31, 2008	'	4,020,000	'	'	0
Net loss	-306,190	0	0	-306,190	0
Balances at Dec. 31, 2009	-1,074,711	4,020	35	-1,078,766	0
Balances (in shares) at Dec. 31, 2009	'	4,020,000	'	'	0
Issuance of Series 1 convertible preferred stock in May 2010 for cash at $0.40 per share - net of issuance costs of $50,000	450,000	0	0	0	450,000
Issuance of Series 1 convertible preferred stock in May 2010 for cash at $0.40 per share - net of issuance costs of $50,000 (in shares)	'	0	'	'	1,250,000
Issuance of Series 1 convertible preferred stock in October 2010 in exchange for convertible promissory notes	195,342	0	0	0	195,342
Issuance of Series 1 convertible preferred stock in October 2010 in exchange for convertible promissory notes (in shares)	'	0	'	'	488,354
Issuance of Series 1 convertible preferred stock in November 2010 for cash at $0.40 per share	40,000	0	0	0	40,000
Issuance of Series 1 convertible preferred stock in November 2010 for cash at $0.40 per share (in shares)	'	0	'	'	100,000
Preferred stock warrants reclassified from liabilities expense	37,110	0	37,110	0	0
Stock-based compensation expense	25,175	0	25,175	0	0
Net loss	-1,207,561	0	0	-1,207,561	0
Balances at Dec. 31, 2010	-1,534,645	4,020	62,320	-2,286,327	685,342
Balances (in shares) at Dec. 31, 2010	'	4,020,000	'	'	1,838,354
Preferred shares converted to common	0	1,838	683,504	0	-685,342
Preferred shares converted to common (in shares)	'	1,838,354	'	'	-1,838,354
Option exercises	183,362	1,469	181,893	0	0
Option exercises (in shares)	'	1,469,338	'	'	0
Merger record ATI shares retired	-7,327	-7,327	0	0	0
Merger record ATI shares retired (in shares)	'	-7,327,692	'	'	0
Effect of reverse recapitalization merger	12,013	45,500	-33,487	0	0
Effect of reverse recapitalization merger (in shares)	'	45,500,000	'	'	0
Merger issuance of stock and record shell common	21,500	21,500	0	0	0
Merger issuance of stock and record shell common (in shares)	'	21,500,000	'	'	0
Option exercise post merger	17,456	738	16,718	0	0
Option exercise post merger (in shares)	'	737,357	'	'	0
Issuance of common stock	1,767,734	13,199	1,754,535	0	0
Issuance of common stock (in shares)	'	13,199,235	'	'	0
Merger expenses	-26,186	0	-26,186	0	0
Stock-based compensation expense	656,252	0	656,252	0	0
Net loss	-4,440,103	0	0	-4,440,103	0
Balances at Dec. 31, 2011	-3,349,944	80,937	3,295,549	-6,726,430	0
Balances (in shares) at Dec. 31, 2011	'	80,936,592	'	'	0
Issuance of preferred stock for services	250,000	0	249,750	0	250
Issuance of preferred stock for services (in shares)	'	0	'	'	250,000
Issuance of common stock	4,324,142	261,580	4,062,562	0	0
Issuance of common stock (in shares)	'	261,580,339	'	'	0
Stock-based compensation expense	383,604	0	383,604	0	0
Net loss	-5,135,618	0	0	-5,135,618	0
Balances at Dec. 31, 2012	-3,527,816	342,517	7,991,465	-11,862,048	250
Balances (in shares) at Dec. 31, 2012	'	342,516,931	'	'	250,000
Preferred shares converted to common	126,684	8,094	118,840	0	-250
Preferred shares converted to common (in shares)	'	8,094,117	'	'	-250,000
Preferred stock - Series C issued to officers as compensation	38,550	0	37,800	0	750
Preferred stock - Series C issued to officers as compensation (in shares)	'	0	'	'	750,000
Common stock issued for services	860,013	21,200	838,813	0	0
Common stock issued for services (in shares)	'	21,199,822	'	'	0
Common stock issued to acquire intangible assets	79,000	2,000	77,000	0	0
Common stock issued to acquire intangible assets (in shares)	'	2,000,000	'	'	0
Common stock issued in settlement of accounts payable	259,660	7,431	252,229	0	0
Common stock issued in settlement of accounts payable (in shares)	'	7,430,922	'	'	0
Common stock issued in settlement of notes payable	2,200,000	93,860	2,106,140	0	0
Common stock issued in settlement of notes payable (in shares)	'	93,860,499	'	'	0
Common stock issued upon conversion of convertible promissory notes	1,559,195	98,456	1,460,739	0	0
Common stock issued upon conversion of convertible promissory notes (in shares)	'	98,455,794	'	'	0
Common stock issued for Series D convertible preferred stock dividend	0	414	12,002	-12,416	0
Common stock issued for Series D convertible preferred stock dividend (in shares)	'	413,860	'	'	0
Loss on issuance of common stock	352,096	0	352,096	0	0
Common stock issued upon exercise of common stock options	0	200	-200	0	0
Common stock issued upon exercise of common stock options (in shares)	'	200,000	'	'	0
Debt discount written off - associated with convertible promissory notes	-250,000	0	-250,000	0	0
Beneficial conversion feature - debt discount - convertible promissory notes	225,996	0	225,996	0	'
Beneficial conversion feature - Series D Convertible Preferred stock	320,500	0	320,500	0	'
Relative fair value associated with senior secured convertible debentures issued with detachable warrants	1,938,930	0	1,938,930	0	'
Convertible promissory notes converted and associated reclassification of derivative liability	2,712,000	0	2,712,000	0	'
Series D convertible preferred stock 8% dividend accrued at period end	-25,986	0	0	-25,986	'
Stock-based compensation expense	743,689	0	743,689	0	0
Net loss	-15,131,681	0	0	-15,131,681	0
Balances at Dec. 31, 2013	($7,519,170)	$574,172	$18,938,039	($27,032,131)	$750
Balances (in shares) at Dec. 31, 2013	'	574,171,945	'	'	750,000

Consolidated_Statement_of_Shar

Consolidated Statement of Shareholders' Equity (Parenthetical) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2010	Dec. 31, 2008
Preferred Stock, Dividend Rate, Percentage	8.00%	'	'
Issuance Of Common Stock, Per Share Value	'	'	$0.00
Issuance Of Series 1 Convertible Preferred Stock, Per Share Value One	'	$0.40	'
Payments of Stock Issuance Costs	'	$50,000	'
Issuance Of Series 1 Convertible Preferred Stock, Per Share Value Two	'	$0.40	'

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended		72 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Cash flows from operating activities	'	'	'
Net loss	($15,131,681)	($5,135,618)	($26,627,858)
Adjustments to reconcile net loss to net cash used in operating activities	'	'	'
Depreciation and amortization	0	7,260	33,014
Amortization of debt discount	1,768,093	655,881	2,423,974
Amortization of deferred financial costs	253,110	13,091	266,201
Amortization of intangibles	70,049	0	70,049
Stock issued for services	860,013	1,637,696	2,497,709
Loss on debt issuance	6,708,728	0	6,708,728
Loss on stock issuance	352,096	672,414	1,024,510
Gain on disposal of equipment	0	1,129	-2,621
Preferred stock Series C issued as compensation	38,550	0	38,550
Stock-based compensation expense	743,689	383,604	1,808,720
Non-cash interest expense related to warrants and derivatives	0	0	763,316
Change in fair value of warrants and derivative liabilities	-271,191	-485,006	-1,148,597
Common stock issued at conversion of Series A preferred stock	126,684	0	126,684
Gain on settlement of convertible note and warrants	0	0	-137,632
Changes in assets and liabilities	'	'	'
Prepaid expenses and other current assets	367,757	-166,025	-133,766
Accounts payable	87,719	1,184,118	3,478,376
Accrued liabilities and other non-current liabilities	548,705	77,477	743,732
Related party liabilities	4,442	-147	-139,345
Net cash used in operating activities	-3,473,237	-1,154,126	-8,206,256
Cash flows from investing activities	'	'	'
Acquisition of property and equipment	0	0	-40,392
Acquisition of other assets	-70,000	-55,000	-125,000
Security deposit write-off	0	-1,000	-1,000
Net cash used in investing activities	-70,000	-56,000	-166,392
Cash flows from financing activities	'	'	'
Proceeds from borrowings	5,047,846	1,413,430	7,718,824
Repayment of borrowings	-303,715	-47,000	-450,715
Proceeds from issuance of common stock	0	0	1,797,941
Proceeds from issuance of stock options	0	0	200,818
Proceeds from issuance of convertible preferred stock	0	0	540,000
Costs of financings	-325,434	0	-401,621
Proceeds from sale of warrant	0	0	35
Net cash provided by financing activities	4,418,697	1,366,430	9,405,282
Net increase (decrease) in cash and cash equivalents	875,460	156,304	1,032,634
Cash and cash equivalents, beginning of period	157,174	870	0
Cash and cash equivalents, end of period	1,032,634	157,174	1,032,634
Supplemental schedule of non-cash activities:	'	'	'
Bifurcation of derivatives embedded in convertible notes	0	0	548,053
Beneficial conversion feature - Series D convertible preferred stock	320,500	0	320,500
Beneficial conversion feature - debt discount - convertible promissory notes	225,996	0	225,996
Relative fair value associated with senior secured convertible debentures issued with detachable warrants	1,938,930	0	1,938,930
Convertible promissory notes converted and associated reclassification of derivative liability	2,712,000	0	2,712,000
Debt discount written off - associated with convertible promissory notes	-250,000	0	-250,000
Debt discount associated with convertible promissory notes - derivative liability	812,500	0	812,500
Stock warrants reclassified from liabilities to equity	0	0	39,142
Preferred stock issued in lieu of payment of payable	0	250,000	250,000
Preferred stock Series D issued for accounts payable	1,169,394	0	1,169,394
Convertible promissory notes issued for payables and accrued liabilities	123,410	305,932	653,037
Convertible notes payable issued for accounts payables	160,715	0	160,715
Issuance of warrants to investors	0	371,180	371,180
Stock issued for prepaid expenses	0	31,188	31,188
Payables forgiven for property and equipment	0	10,000	10,000
Stock issued to acquire intangible assets	79,000	477,143	556,143
Stock issued to satisfy accounts payable and accrued expenses	259,660	560,808	820,468
Stock issued for notes payable	2,200,000	0	2,200,000
Stock issued for convertible debt	1,559,195	964,982	2,524,177
Intrinsic value of beneficial conversion feature	0	224,985	224,985
Reclassification of warrants to APIC	0	2,032	2,032
Supplemental Cash Flow Information:	'	'	'
Interest paid	$60,553	$0	$60,533

GENERAL

GENERAL	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Nature Of Operations [Text Block]	'
		1	General
	Amarantus Bioscience Holdings, Inc. (the “Company”) is a Nevada corporation that was formed to facilitate a merger with Amarantus BioScience, Inc., a Delaware corporation that was incorporated on January 14, 2008. The Company is a development stage biopharmaceutical drug development company dedicated to sourcing high-potential therapeutic platform technologies and aligning their development with complementary clinical-stage compounds to reduce overall enterprise risk. Through December 31, 2013, the Company has been primarily engaged in biotechnology research and development and raising capital to fund its operations.
	On April 5, 2013, the Company (formerly known as Amarantus Bioscience, Inc.) filed a Certificate of Amendment to its Articles of Incorporation with the Secretary of State of Nevada, pursuant to which the Company’s name was changed from Amarantus Bioscience, Inc. to Amarantus Bioscience Holdings, Inc.

DEVELOPMENT_STAGE_AND_GOING_CO

DEVELOPMENT STAGE AND GOING CONCERN	12 Months Ended
	Dec. 31, 2013
Development Stage And Going Concern [Abstract]	'
Development Stage And Going Concern [Text Block]	'
	2	Development Stage and Going ConcerN
	The Company’s activities since inception have consisted principally of acquiring product and technology rights, raising capital, and performing research and development. The Company is considered to be in the development stage as of December 31, 2013, as our principal commercial operations have not commenced. Successful completion of the Company’s development programs and, ultimately, the attainment of profitable operations are dependent on future events, including, among other things, its ability to access potential markets; secure financing, develop a customer base; attract, retain and motivate qualified personnel; and develop strategic alliances. From inception, the Company has been funded by a combination of equity and debt financings. Although management believes that the Company will be able to successfully fund its operations, there can be no assurance that the Company will be able to do so or that the Company will ever operate profitably.
	The Company expects to continue to incur substantial losses over the next several years during its development phase. To fully execute its business plan, the Company will need to complete certain research and development activities and clinical studies. Further, the Company’s product candidates will require regulatory approval prior to commercialization. These activities may span many years and require substantial expenditures to complete and may ultimately be unsuccessful. Any delays in completing these activities could adversely impact the Company. The Company plans to meet its capital requirements primarily through issuances of debt and equity securities and, in the longer term, revenue from product sales.
	The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (GAAP), which contemplate continuation of the Company as a going concern. As of December 31, 2013, the Company had cash and cash equivalents of $1,032,634. During the year ended December 31, 2013, the Company incurred a net loss of $15,131,681 and had negative cash flows from operating activities of $3,473,237. In addition, the Company had an accumulated deficit of $27,032,131 at December 31, 2013. The Company believes its current capital resources are not sufficient to support its operations. Management intends to continue its research efforts and to finance operations of the Company through debt and/or equity financings. Management plans to seek additional debt and/or equity financing through private or public offerings or through a business combination or strategic partnership. There can be no assurance that the Company will be successful in obtaining additional financing on favorable terms, or at all. These matters raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of these uncertainties.
	SIGNIFICANT ACCOUNTING POLICIES
	Principles of Consolidation - The Consolidated Financial Statements include the accounts of Amarantus BioScience Holdings, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated.
	Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
	Certain Significant Risks and Uncertainties - The Company participates in a global, dynamic, and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; regulatory approval and market acceptance of the Company’s products; development of the necessary manufacturing capabilities and the Company’s ability to obtain adequate resources of necessary materials; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees and other resources necessary to support its growth.
	Concentration of Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents. The Company places its cash and cash equivalents with domestic financial institutions that are federally insured within statutory limits.
	Cash and Cash Equivalents - The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
	Intangible Assets – Intangible assets or certain rights to use certain intangible assets for the Company’s research and development activities are capitalized as assets in cases where the Company has determined that those assets have an identifiable alternative future use in accordance with US GAAP. If the Company concludes that those assets have useful lives that are indeterminable then they are assumed to be indefinite lived unless. In 2013 the Company determined that the useful lives of those assets can be reasonable estimated and in which case those assets are being amortized to expense over their estimated useful lives of between 10.9 years and 18.5 years depending on the patent expire date.
	Impairment of Long-Lived Assets- The Company reviews the carrying value of long-lived assets, including intangible assets and property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. There have been no impairments for the years ended December 31, 2013 and 2012.
	Restatement of Prior Quarters
	In the fourth quarter of 2013, we discovered that some of the amounts we had previously reported in prior quarters had not been recorded correctly. The adjustments to correct for accounting differences were made in the fourth quarter of 2013 and are primarily related to our accounting for convertible note obligations.
	The following table sets forth the effects of the restatement on affected items within our previously reported Consolidated Balance Sheets for the periods ended March 31, 2013, June 30, 2013 and September 30, 2013 had the adjustments been made in the corresponding quarters.
		March 31, 2013				June 30, 2013				September 30, 2013
		As Reported		As Restated		As Reported		As Restated		As Reported		As Restated
	Derivative liabilities		921,954		794,468		250,011		419,239		1,544,443		2,427,367
	Convertible promissory notes		328,727		328,726		674,161		631,961		485,936		475,780
	Total Liabilities		6,165,888		6,038,401		5,576,483		5,703,511		4,664,706		5,537,474
	Additional paid in capital		9,367,041		11.274,893		10,728,916		12,678,967		13,760,385		16,053,726
	Deficit accumulated during the development stage		-14,719,336		-16,499,701		-15,620,221		-17,697,300		-17,645,773		-20,737,511
	Stockholder’s deficit	$	-4,967,128	$	-4,839,641	$	-4,449,302	$	-4,576,330	$	-3,354,569	$	-4,152,966
	The following table sets forth the effects of the restatement on affected items within our previously reported Consolidated Statement of Operations for the three months ended March 31, 2013, June 30, 2013 and September 30, 2013 had the adjustments been made in the corresponding quarters.
		March 31, 2013				June 30, 2013				September 30, 2013
		As Reported		As Restated		As Reported		As Restated		As Reported		As Restated
	Operating loss	$	-1,884,597	$	-1,884,597	$	-1,304,475	$	-1,304,475	$	-678,548	$	-678,548
	Non-operating income (loss)		-972,691		-2,753,056		403,590		106,876		-1,346,964		-2,361,623
	Net loss		-2,857,288		-4,637,653		-900,885		-1,197,599		-2,025,512		-3,040,171
	Net loss per common share, basic and diluted	$	-0.01	$	-0.01	$	0	$	0	$	0	$	-0.01
	The following table sets forth the effects of the restatement on affected items within our previously reported Consolidated Statement of Operations for the six and nine months ended June 30, 2013 and September 30, 2013, respectively had the adjustments been made in the corresponding quarters.
		June 30, 2013				September 30, 2013
		As Reported		As Restated		As Reported		As Restated
	Operating loss	$	-3,189,072	$	-3,189,072	$	-3,867,619	$	-3,867,619
	Non-operating loss		-569,101		-2,646,180		-1,916,066		-5,007,804
	Net Loss	$	-3,758,173	$	-5,835,252	$	-5,783,685	$	-8,875,423
	Net loss per common share, basic and diluted	$	-0.01	$	-0.01	$	-0.01	$	-0.02
	Revenue Recognition - The Company recognizes revenue when the earnings process is complete, when revenue is realized or realizable and earned, when persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable, and collectability is reasonably assured.
	The Company accounts for milestones related to research and development activities in accordance with the milestone method of revenue recognition of Accounting Standards Codification Topic 605-28, under which consideration contingent on the achievement of a substantive milestone is recognized in its entirety in the period when the milestone is achieved. A milestone is considered to be substantive when it meets all of the following criteria: the milestone is commensurate with either the performance required to achieve the milestone or the enhancement of the value of the delivered items resulting from the performance required to achieve the milestone; the milestone relates solely to past performance; and, the milestone is reasonable relative to all of the deliverables and payment terms within the agreement.
	To date, the Company has only received research grant revenue and contract revenue. Research grant revenue and contract revenue is recognized as the Company provides the services stipulated in the underlying agreement based on the time and expenditures incurred, and all terms required in the agreement have been met.  Amounts received in advance of services provided are recorded as deferred revenue and amortized as revenue when the services are provided.
	Research and Development Expenditures - Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. Research and development activities are also separated into three main categories: research, clinical development, and biotechnology development. Research costs typically consist of preclinical and toxicology costs. Clinical development costs include costs for Phase 1 and 2 clinical studies. Biotechnology development costs consist of expenses incurred in connection with product formulation and analysis. The Company charges research and development costs, including clinical study costs, to expense when incurred.
	Fair Value of Financial Instruments - The fair value of certain of the Company’s financial instruments, including cash and cash equivalents, accrued compensation, and other accrued liabilities, approximate cost because of their short maturities. The Company measures the fair value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:
	•   Level 1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.
	•   Level 2-Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•   Level 3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
	Stock-Based Compensation - Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	Expected Term — The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.
	Expected Volatility — The Company computes stock price volatility over expected terms based on its historical common stock trading prices.
	Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term.
	Expected Dividend — The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.
	Preferred Stock - Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity. At all other times, the Company classifies its preferred shares in stockholders’ deficiency.
	Convertible Instruments – The Company bifurcates conversion options from their host instruments and account for them as free standing derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP.
	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company also records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
	Common Stock Purchase Warrants and Derivative Financial Instruments - The Company classifies all of its common stock purchase warrants and other derivative financial instruments as equity if the contracts (1) require physical settlement or net-share settlement or (2) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (1) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (2) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (3) that contain reset provisions. The Company assesses classification of its common stock purchase warrants and other derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
	Debt Discounts - The Company records, as a discount to notes and convertible notes, the relative fair value of warrants issued in connection with the issuances and the intrinsic value of any conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption.
	Income Taxes - The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.
	In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.
	The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement, attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company’s tax return.
	Net Loss Per Common Shareholder - Basic net loss per share is based upon the weighted average number of common shares outstanding. Diluted net loss per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options, warrants and restricted stock are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.
	Recently Issued Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”, or ASU No. 2013-11, which concludes that, under certain circumstances, unrecognized tax benefits should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. ASU No. 2013-11 will be effective for us beginning January 1, 2014. We do not anticipate that the adoption of this standard will have a material impact on our financial position or results of operations.
	Executive Compensation
	Unpaid bonuses to Gerald E. Commissiong, President and Chief Executive Officer and Dr. John W. Commissiong, Chief Scientific, Officer, were improperly reflected as prepaid expenses and other current assets in form 10-K filed with the Security and Exchange Commission on 4/17/2013, and forms 10-Q filed with the Security and Exchange Commission on 5/12/2013, 8/19/2013 and 11/14/2013. This improper classification was not in conformity with the financial policies of the Company. In the fourth quarter 2013 were paid and thereby eliminating this improper classification. A total bonus of $443,874 was paid in 2014, $230,222 for Gerald E. Commissiong, and $213,763 for Dr. John W. Commissiong

BALANCE_SHEET_DETAILS

BALANCE SHEET DETAILS	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Supplemental Balance Sheet Disclosures [Text Block]	'
	3	BALANCE SHEET DETAILS
	Prepaid expenses and other current assets:
		Year Ended December 31,
		2013		2012
	Prepaid expenses	$	91,853	$	409,710
	Deferred financing costs		109,233		46,909
	Other		14,100		64,001
	Total	$	215,186	$	520,620
	Accrued liabilities:
		Year Ended December 31,
		2013		2012
	Accrued compensation and related benefits	$	266,407	$	18,746
	Series D Convertible Preferred dividend		25,987		—
	Total	$	292,394	$	18,746
	Related party liabilities:
		Year Ended December 31,
		2013		2012
	Promissory note	$	222,083	$	222,083
	Accrued interest		25,884		21,442
	Total	$	247,967	$	243,525
	This promissory note dated March 5, 2008 is due and payable March 5, 2015 and carries a annual interest rate of 2%. The note can be converted at the option of the Company based upon the FMV of common stock as of the date of issuance at the closing price quoted on the exchange on which the Company’s common stock is listed. The conversion price as at December is $0.0798, and would convert to 3,107,356 shares.

FAIR_VALUE_MEASUREMENTS

FAIR VALUE MEASUREMENTS	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Fair Value Disclosures [Text Block]	'
	4		Fair Value Measurements
	Accounting standards have been issued which define fair value, establishes a market-based framework or hierarchy for measuring fair value and expands disclosures about fair value measurements. The standard is applicable whenever another accounting pronouncement requires or permits assets and liabilities to be measured at fair value. The standard does not expand or require any new fair value measures; however its application may change current practice.
	Fair value is defined under the standard as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. The standard also establishes a three-level hierarchy, which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value:
		·	Level 1 — inputs to the valuation methodology are quoted prices (unadjusted) for an identical asset or liability in an active market
		·	Level 2 — inputs to the valuation methodology include quoted prices for a similar asset or liability in an active market or model-derived valuations in which all significant inputs are observable for substantially the full term of the asset or liability
		·	Level 3 — inputs to the valuation methodology are unobservable and significant to the fair value measurement of the asset or liability
	The Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2013 and 2012, by level within the fair value hierarchy, are as follows:
	Fair Value Measurements at December 31, 2013
			Level 1			Level 2		Level 3		Total
	Warrant liability		$	—		$	—	$	—	$	—
	Derivative Liability			—			—		5,859,170		5,859,170
	Total fair value		$	—		$	—	$	5,859,170	$	5,859,170
	Fair Value Measurements at December 31, 2012
			Level 1			Level 2		Level 3		Total
	Warrant liability		$	—		$	—	$	232,988	$	232,988
	Derivative Liability			—			—		26,893		26,893
	Total fair value		$	—		$	—	$	259,881	$	259,881
	The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities from January 1, 2012 to December 31, 2013:
				Warrant Liability		Derivative Liability		Total
	31-Dec-11			283,931			140,706		424,637
	Conversion of warrants to common stock			-2,031			—		-2,031
	Issuance of convertible notes			—			4,044,349		4,044,349
	Change in fair value			-48,912			-4,158,162		-4,207,074
	31-Dec-12			232,988			26,893		259,881
	Issuance of convertible notes			—			8,582,295		8,582,295
	Reclass to additional paid in capital			—			-2,711,816		-2,711,816
	Change in fair value			-232,988			-38,202		-271,190
	31-Dec-13			—		$	5,859,170	$	5,859,170
	As of December 31, 2013 and 2012, the fair value of the warrant liability was $0 and $232,988, respectively. The changes in fair value for the years ended December 31, 2013 and 2012 of $232,988 and $48,912, respectively, have been recorded in the accompanying statements of operations as a component of other income (expense). The fair value of the warrants at December 31, 2013 and 2012 were determined using the Black-Scholes model with the following assumptions:
			2013		2012
	Annualized volatility		331% - 335%		275% - 624%
	Contractual life (years)		0.04		0.5
	Expected dividends		0%		0%
	Risk-free investment rate		0.62 - 0.91%		0.12 - .014%
	Derivative liability
	A number of the Company’s convertible notes contain embedded derivatives wherein their automatic conversion, which is contingent upon a future equity raise, can accelerate the realization of the expected payout for each note. This feature creates the possibility of a greater than expected return for the note holder and thus a higher than expected liability for the Company. The value of this feature was estimated for each note using the probability expected return method, in which the payout of distinct potential early conversion scenarios was discounted to the present using the expected IRR of the note and compared with the present value of the note if held to maturity. Probabilities were applied to the value of early conversion in each scenario to arrive at a probability-weighted value of the early conversion feature.
	For certain convertible note obligations, the Company is required to measure and record a related derivative liability, representing the estimated fair value of any embedded conversion options. As of December 31, 2013 and December 31, 2012, the fair value of the derivative liability was $5,859,170 and $26,893, respectively. The changes in fair value for the twelve months ended December 31, 2013 and December 31, 2012 is $13,000, and $436,095,  have been recorded in the accompanying statements of operations as a component of other income (expense).

NET_LOSS_PER_SHARE

NET LOSS PER SHARE	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Earnings Per Share [Text Block]	'
	5	Net loss per share
	The following table sets forth the computation of the basic and diluted net loss per share attributable to Amarantus common stockholders for the periods indicated:
			Year Ended December 31,
			2013			2012
	Numerator
	Net Loss		$	-15,131,681		$	-5,135,618
	Preferred stock dividend			38,402			—
	Net loss applicable to common stockholders		$	-15,170,083		$	-5,135,618
	Denominator
	Weighted average shares outstanding during the period:
	Common stock - basic			450,931,510			140,710,454
	Common shares equivalents			—			—
	Common stock - diluted			450,931,510			140,710,454
	Net loss per share		$	-0.03		$	-0.04
	Potentially dilutive securities:
	Outstanding time-based common stock options(1)		6,941,000		-	-2
	Outstanding time-based preferred stock options(1)		2,288,000		-	-2
	Warrants(1)		84,553,000		-	-2
	Relating party liabilities		3,107,000		-	-2
	Convertible promissory note(s)(1)		6,325,000		-	-2
	8% Senior convertible debentures		75,000,000		-	-2
	Convertible preferred stock(1) (3)		753,000		-	-2
	-1	The impact of time-based stock options, warrants, the convertible notes and the convertible preferred stock on earnings per share is anti-dilutive in a period of loss from continuing operations.
	-2	Total anti dilutive securities in 2012 was approximately 84,000,000.
	-3	Includes Series C and D Convertible Preferred Stock.

INTANGIBLE_ASSETS

INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and Intangible Assets Disclosure [Text Block]	'
	6	INTANGIBLE ASSETS
	The following table summarizes our intangible assets:
		Year Ended December 31,
		2013		2012
	Intangible assets:
	License – Power 3 Medical	$	430,252	$	484,643
	License – Memory Dx (LymPro)		145,940	$	47,500
	License – University of Massachusetts		34,902		—
	Total intangible assets net	$	611,094	$	532,143
	Amortizable intangible assets as of December 31, 2013 and 2012 consist of the following:
		December 31, 2013
		Gross		Accumulated		Net Book
		Carrying		Amortization		Value
		Amount
	License costs		681,143		-70,049		611,094
		December 31, 2012
		Gross		Accumulated		Net Book
		Carrying		Amortization		Value
		Amount
	License costs	$	532,143	$	—	$	532,143
	These license costs will be amortized over their patent expire date. As of December 31, 2013, amortization expense for the next five years is expected to be as follows:
	2014	$	44,599
	2015		44,599
	2016		44,721
	2017		44,599
	2018		44,599
	thereafter		387,977
	Total	$	611,094
	Power 3 Medical License and subsequent asset purchase
	The Company acquired a license and the intellectual property rights to 2 diagnostic blood test platforms known as NuroPro and BC-SeraPro from Power3 Medical Products, Inc. in 2012. NuroPro is a neurodegenerative disease diagnostic platform with a lead application in Parkinson’s disease. BC SeraPro is an oncology diagnostic platform with a lead application in Breast Cancer. In December of 2012, the Company acquired all of the assets from the bankruptcy estate of Power3 Medical Products, Inc.
	Memory Dx (LymPro) License
	On December 14, 2012, the Company entered into an exclusive license agreement (the “License Agreement”) with Memory Dx, LLC (“MDx”) under which MDx granted to the Company an exclusive worldwide license to develop, manufacture, market, sell and import medical devices under MDx’s intellectual property pertaining to Alzheimer’s disease diagnosis (the “License”). As consideration for the License, the Company issued 2,000,000 shares of its common stock at $0.0395 per share to MDx in March 2013 and will pay MDx a royalty equal to 9% of the net proceeds of all sales resulting from the License. Further, MDx, with the Company’s engagement, is to complete a validation study regarding a blood test for the detection of Alzheimer’s disease. To prepare the laboratory for this study, the Company paid MDx $50,000 in 2013. The Company will also assist MDx in fund raising, and, upon successful completion of the validation study, pay MDx $1,000,000 in cash or Company stock. The Company may sell, sub-license or assign the License Agreement and has an option to terminate the License Agreement upon 30 days written notice if MDx is unable to meet its obligations regarding the validation study.
	University of Massachusetts License
	On December 12, 2013, the Company entered into a licensing arrangement with the University of Massachusetts whereby the Company obtained an exclusive world-wide royalty bearing license to conduct research, develop and commercialize intellectual property related to soluble MANF in Pancreatic Beta-Cell Disorders. The Company paid an upfront fee of $35,000 upon entering into the agreement. Under the agreement, the Company has certain obligations to use commercially reasonable efforts to develop and commercialize the licensed patents. The agreement provides for specific milestone payments to be made to the university upon the occurrence of certain development related events. The agreement also provides that the Company will pay certain minimum and sales-based royalties to the university once product sales are commenced. Under the agreement, the Company is obligated to reimburse the university for all costs related to maintaining the licensed patents. The Company may terminate the agreement for any reason upon 90 days’ written notice.

COLLABORATIVE_AGREEMENTS

COLLABORATIVE AGREEMENTS	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Collaborative Arrangement Disclosure [Text Block]	'
	7	collaborative agreements
	University of Massachusetts
	The Company has entered into a series of exclusive license agreements with the University of Massachusetts (the “UMass”) on December 12, 2013 that provide the Company with certain technology and related patent rights and materials associated with Mesencdphalic Astrocyte derived Neurotrophic Factor, or MANF-based therapeutics.
	Under the terms of the agreements, the Company pays license fees and specified development costs and will be required to pay royalties amounting to 2% of net sales of products originating from the licensed technologies. The agreements will expire at the end of the life of the last issued patent.
	The Company incurred license fees and specified development costs under the UMass agreements of $34,441 for the year ended December 31, 2013, which are included in research and development expense.

CONVERTIBLE_NOTES_PAYABLE

CONVERTIBLE NOTES PAYABLE (Convertible Notes Payable [Member])	12 Months Ended
	Dec. 31, 2013
Convertible Notes Payable [Member]	'
Debt Disclosure [Text Block]	'
	8	Convertible Notes Payable
	The following table summarizes the Company’s outstanding convertible notes payable obligations:
							Principal Balance Outstanding
	Issue Date	Maturity Date	Stated			Conversion Terms	December 31,		December 31,
			Interest Rate				2013		2012
	11/14/12	6/3/13		10	%	Fixed at $0.10	$	0	$	600,000
	10/4/11	9/6/14		20	%	$0.05 subject to adjustments		0		140,000
						Notes payable, current	$	0	$	740,000
	Subsequent to December 31, 2013, the Company issues approximately 93,860,000 shares of common stock to settle the convertible notes payable and accrued interest.

8_SENIOR_CONVERTIBLE_DEBENTURE

8% SENIOR CONVERTIBLE DEBENTURES (8% Senior Convertible Debentures [Member])	12 Months Ended
	Dec. 31, 2013
8% Senior Convertible Debentures [Member]	'
Debt Disclosure [Text Block]	'
	9	8% SENIOR Convertible DEBENTURES
	The following table summarizes the Company’s outstanding 8% convertible promissory note obligations:
						Principal Balance Outstanding
	Issue Date	Maturity	Stated		Conversion Terms	December 31, 2013		December 31,
		Date	Interest					2012
			Rate
	10/2/13	10/2/14	8	%	Variable conversion price	$	1,788,889	$	0
	-0.000745156	9/6/14	8	%	Variable conversion price		1,544,443		-0-
		Sub total					3,333,332		0
		Discount on convertible promissory notes					-2,401,390		-0-
		Current portion of 8% convertible promissory notes, net				$	931,942	$	0
	Subsequent to December 31, 2013 all the 8% senior convertible debentures converted to capital stock of the Company.
	The Debenture agreement provides that the Company may be obligated to pay partial liquidated damages to certain Investors in the event that the company is unable to deliver Common Stock pursuant to the terms of the agreement upon an elected conversion. The amount of liquidated damages is determined based on a fixed dollar amount per trading day during which the conversion shares remain undelivered.
	The Company entered into a registration rights agreement with the Investors pursuant to which the Company filed a registration statement with the Securities and Exchange Commission. The registration statement went effective February 4, 2014.

CONVERTIBLE_PROMISSORY_NOTES

CONVERTIBLE PROMISSORY NOTES (Convertible Promissory Notes Payable [Member])	12 Months Ended
	Dec. 31, 2013
Convertible Promissory Notes Payable [Member]	'
Debt Disclosure [Text Block]	'
	10	Convertible Promissory Notes
	The following table summarizes the Company’s outstanding convertible promissory note obligations:
							Principal Balance Outstanding
	Issue Date	Maturity	Stated			Conversion Terms	December 31, 2013		December 31,
		Date	Interest						2012
			Rate
	6/5/13	12/2/13		6	%	Fixed at $0.02		20,000		-0-
	11/4/12	5/3/13		6	%	Fixed at $0.01		10,173		10,173
	8/23/12	2/19/13		6	%	Fixed at $0.015		50,000		50,000
	Nov-12	On Demand		None		Variable conversion price		720		720
	6/6/11	6/6/13		5	%	Fixed at $0.04		10,000		10,000
	4/11/11	4/11/13		5	%	Fixed at $0.04		25,000		25,000
	5/1/11	5/1/13		5	%	Fixed at $0.10		4,250		4,250
	4/1/11	4/1/13		5	%	Variable conversion price		4,250		4,250
	09/21/2012-09/01/2013	03/20/2013-06/05/2013		6	%	Fixed prices ranging from $0.0051-$0.0545				154,900
	12/28/10	On Demand		5	%	Fixed at $0.0030				13,000
	12/28/2010– 06/09/2011	12/6/11		5	%	Variable conversion price				375,000
	8/21/12	2/21/13		None		Variable conversion price				6,066
	12/13/10	12/13/12		5	%	Variable conversion price				100,000
	6/6/12	12/3/12		6	%	Fixed at $0.03				13,000
	9/26/11	3/24/12		6	%	Fixed at $0.10				3,000
	4/27/11	4/27/13		5	%	Variable conversion price		-0-		50,000
		Sub total						124,393		819,359
		Discount on convertible promissory notes						-0-		-50,467
		Current portion of convertible promissory notes, net					$	124,393	$	768,892
	For notes that converted to common stock during the year ended December 31, 2013, the Company issued approximately 98,456,000 shares of common stock and extinguished approximately $3,463,162 of principal obligations as a result of those conversions.
	Convertible notes in default
	At December 31, 2013, the Company was in technical default of certain convertible notes with an aggregate principal balance outstanding of approximately $124,000 that were due prior to December 31, 2013
	If the registration statement at any time ceases to be effective or if the Investors are not permitted to utilize the prospectus related to the registration statement to resell securities intended to be registered therein for more than 10 consecutive calendar days or for more than an aggregate of 15 calendar days during any twelve month period, then the Company is obligated to pay the affected Investors an amount in cash, as partial liquidated damages, equal to 2% multiplied by the aggregate subscription amount paid by the Investors each month until such condition is cured, plus interest if any such liquidated damages are paid beyond a specified payment date as provided for in the agreement.
	2013 Restructuring of Certain Convertible Debentures and Related Warrants
	On February 7th, 2013, the Company completed a series of transactions related to the restructuring of certain convertible debentures and related warrants that were in default. As a result, the Company executed two separate amended and restated Convertible Promissory Notes in the amounts of $375,000 and $187,500 (the “New Notes”), respectively, payable to Dominion Capital, LLC. The Company had defaulted on Promissory Notes issued in 2011 to certain individual investors in the total aggregate amount of $375,000 (the “Old Notes”), and related cashless warrants in the amount of $500,000. Dominion capital paid $562,500 to acquire the Old Notes, and as part of the transaction all of the related warrants have been retired, inclusive of a $37,500 payment from the Company to certain warrant holders. The Old Notes and Related warrants had a conversion feature equal to a 66.6% floorless discount to a ‘Next Equity Financing’, defined as a financing where equity, or debt that was convertible into common stock, with a fixed price conversion feature. As a result of the 30 January financing previously announced, the Old Notes and Warrants, inclusive of interest, would have been convertible into approximately $900,000 in common shares priced at $0.0333/share, which would have equated to 27,000,000 common shares.
	As a result, of the transactions listed above, $375,000 in notes became immediately convertible at a price of $0.015/share, equal to 25,000,000 common shares. The $187,500 is also priced at $0.015/share, however the note was not convertible for 6 months and the Company retains an option to repurchase this note at any time until maturity. The $187,500 note was converted into 12,500,000 common shares in July 2013.
	Concurrently, the Company retired a series of convertible notes with unfavorable financing terms that were issued between June 30, 2012 and November 1, 2012.
	As a result of these transactions, the Company eliminated the costly potential default and reset provisions associated with the Old Notes and Warrants that the Company believes were a potential impediment to future growth and more favorable future financing alternatives. With the retirement of the Old Notes and repurchase by the Company of the Warrants, the Company is no longer in default of any convertible notes or warrants, and has eliminated the risk of further dilutive potential of resets and default provisions contained within those retired instruments. The company believes that this has streamlined and enhanced its capital structure placing the Company in a better position to move forward with the execution of its scientific advancement plans.
	January 2013 Convertible Promissory Note Amendment
	On January 30, 2013, the Company executed an amendment to a Convertible Promissory Note payable to Dominion Capital, LLC or its registered assigns (the “Dominion Note”), dated November 14, 2012, providing for an increase in the purchase price for such note from $600,000 to $2,000,000, to be disbursed in tranches through April 26, 2013. The Dominion Note bears interest at the rate of ten percent (10%) per annum until paid in full and is convertible into shares of the Company’s common stock, subject to certain restrictions, at a price of $0.10 per share. The Dominion Note has been amended to provide for an extended amortization schedule with a final maturity date of 28 October 2013. The Company has the option to pay the Dominion Note in cash or stock at its discretion, subject to certain conditions. The Company intends to apply the proceeds from the amended Dominion Note for working capital purposes. Dominion is not able to begin to convert the note until May 14, 2013. The Company received all $600,000 from the initial agreement in 2012, and received the first tranche of funding of $250,000 on January 30th, 2013. The extended amortization schedule provides for payments of $200,000 to $250,000 every 2 weeks until the end of April 2013. The amended notes were converted in fiscal 2013.

COMMITMENTS_AND_CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and Contingencies Disclosure [Text Block]	'
	11	commitments and contingencies
	Lease Arrangements — The Company leases its main office facility and laboratory space in San Francisco, CA under a one-year lease agreement with QB3 Incubator Partners, LP. The lease agreement was entered into in October 2013 and provides for rental payments of $6,700 per month.
	Rent expense for the years ended December 31, 2013 and 2012 was $29,511 and $33,596, respectively.
	Contingencies — From time to time, the Company may become involved in litigation. On January 6, 2012, the Company was served a summons regarding the filing of a lawsuit (Complaint for Breach of Contract, Specific Performance and Common Counts) against the Company by a former consultant to the Company, Peter Freeman v. Amarantus Biosciences, Inc. In August 2012, the Company reached a settlement with Mr. Freeman whereby he received payment of $44,000 in monthly installments of $5,000, and the settlement amounts were fully paid in the year ended December 31, 2012.
	Amarantus is continuing to review the Company’s legal options with respect to the material misrepresentations made by the officers of Power3 Medical and the Company’s rights in the IP.
	The Company is in non-payment of certain convertible notes that were due prior to December 31, 2013, and is also late with regard to making payments to various trade account vendors for goods and services received. Presently the Company is not aware of any accounts that have been turned over to collection agencies or that might result in a lawsuit with the Company.
	The Company incurred various obligations related to the original acquisition of its intellectual property around the time the Company was founded. These transactions are described more fully in Note 16, including a reference to contingent obligations reflected in the financial statements.

PREFERRED_STOCK

PREFERRED STOCK	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Preferred Stock [Text Block]	'
	12	PREFERRED STOCK
	Series A Convertible Preferred Stock
	In May 2012, the Company designated a class of preferred stock as Series A Convertible Preferred Stock. The Series A shares have no entitlement to dividends and have no voting rights. In any event of dissolution, liquidation or winding up of the Company, the Series A shares are entitled to receive a stated value of $1.00 per share. All distributions made to holders of the Series A shares and to holders of other stock of the Company upon liquidation shall be made on a pari passu basis with distributions made to holders of the Company’s common stock. The series A shares are convertible into the Company’s common stock at a stated conversion price that is equal to the lessor of 1) 110% of the closing common stock price on the date of conversion or 2) 80% of the lowest closing common stock price occurring during a 30 trading day period prior to notice of conversion. During 2013 the registered holder of the Company’s Series A convertible preferred stock converted all 250,000 shares into 8,094,117 shares of the Company’s common stock. The Series A Convertible Preferred Stock was converted in January 2013 as part of a services settlement with a vendor.
	Series B Preferred Stock
	On April 2, 2013 the Company filed a Certificate of Designation with the State of Nevada formally creating a series of Series B Convertible Preferred Stock. The Series B Convertible Preferred Stock has no anti-dilution provisions, can only be issued to officers, directors and advisors of the Company, and cannot be converted into common stock, transferred, sold or disposed of in any manner for 24 months.
	Series C Convertible Preferred Stock
	On April 1, 2013, the Company filed a Certificate of Designation with the State of Nevada creating a series of Series C Convertible Preferred Stock. The Series C Convertible Preferred Stock has no anti-dilution provisions, can only be issued to officers and directors of the Company, is convertible into a cumulative total of 750,000 common shares and is automatically convertible into common stock upon listing of the Company’s common stock to a national stock exchange. The holders of Series C shares are entitled to 300 common stock equivalent votes per share on all corporate matters except those that by law only require a single series vote.
	Series D Convertible Preferred Stock
	On August 19, 2013, the Company entered into a securities purchase agreement with an institutional investor (the “Investor”) pursuant to which the Company issued shares of newly designated Series D 8% Convertible Preferred Stock (”Series D Preferred Stock”) to the Investor in exchange for the Investor agreeing to paying off certain accounts payables of the Company, up to an aggregate approximate amount of $1,250,000. In addition, the Company granted to the Investor the right to participate in future financings of the Company until 12 months from the date of the last closing.
	On August 19, 2013, the Company filed a Certificate of Designation designating 1,300 of our preferred stock as Series D Preferred Stock. Each share of Series D Preferred Stock has a stated value of $1,000 and pays on a quarterly basis 8% cumulative dividends per annum. Dividends are payable by the Company in cash or at the Company’s option, in shares of common stock. The Series D Preferred Stock shall have no voting rights except in certain circumstances which would adversely affect the Series D Preferred Stockholders. Each share of Series D Preferred Stock is convertible at any time into shares of common stock by dividing the stated value per share by the then effective conversion price. The conversion price for the Series D Preferred Stock shall equal $0.03 per share, subject to adjustment;  provided,  however , in the event that during any period that the Series D Preferred Stock is outstanding, a holder delivers a conversion notice within 5 trading days following a period that the average of 5 consecutive Volume Weighted Average Prices (VWAPs) is less than $0.02, the conversion price shall be thereafter reduced, and only reduced, to equal the lesser of the then conversion price and 75% of the average of the lowest 5 consecutive VWAPs prior to the delivery of such conversion notice.   The Series D Preferred Stock is also subject to redemption by the Series D Shareholders upon certain triggering events. The redemption amount upon any triggering event is equal to the greater of 1) 130% of the stated value or 2) the stated value divided by the then conversion price multiplied by the VMAP on the trading day immediately preceding the triggering event, plus any accrued and unpaid dividends. The redemption payment may, at the option of the holder, be in cash or shares. Redemption triggering events may include certain events such as 1change of control, bankruptcy, junior security redemptions, common stock delisting, or other adverse events as described under the agreement.
	Stock Warrants
	Company issued 83,333,251 Warrants in 2013 in connection with the Debenture and Warrant transaction. The Warrants are exercisable for a term of three years from the date of issuance at an exercise price of $0.06 per share. The Warrants are exercisable on a cashless basis if at any time after the six months anniversary there is no effective registration statement or current prospectus available for the resale of the shares underlying the Warrants. The Company may call the warrants at an exercise price of $.001 per share if certain conditions as described in the Warrant are met.
	The following table summarizes the Company’s warrant activity for the year ended December 31, 2013.
			Number of Warrants		Weighted Average Exercise Price
	Outstanding as of December 31, 2011			1,392,251	$	0.07
	Issued in connection with convertible debt offerings			11,364,773		0.07
	Exercised			-146,694		0.17
	Expired			-25,501		0.01
	Outstanding as of December 31, 2012			12,584,829		0.04
	Issued in connection with convertible debt offerings			83,333,250		0.06
	Exercised			-		0
	Cancelled			-11,364,773		0.04
	Expired			-		0
	Outstanding as of December 31, 2013			84,553,306		0.06
	Warrant Exchange
	On March 7th, the Company accepted elections to exercise certain warrants in the aggregate amount of 60,000,000 shares of common stock for gross proceeds of $3,600,000. The total proceeds from the transaction were received by the Company in the first quarter of 2014. Pursuant to the offer to exercise dated February 13, 2014 as supplemented on March 6, 2014, the holders of outstanding warrants to purchase shares of common stock of the Company at a price of $0.06 (the “Original Warrants”) were offered the opportunity to exercise their Original Warrants and receive warrants (the “New Warrants”) to purchase three (3) shares of common stock of the Company for every four (4) Original Warrants exercised. The New Warrants are exercisable at a price of $0.12 for a term of five (5) years. The New Warrants are callable by the Company if the Volume Weighted Average Price (VWAP) of the Company’s common stock for each of 20 consecutive trading days exceeds $0.18 and certain equity conditions are met. . The Company may also call the New Warrants if the closing price of the Company’s common stock exceeds $0.18 on the date that is the earlier of the receipt by the Company of an approval letter for listing of the Company’s common stock on an exchange or listing of the common stock on an exchange. The holders of the New Warrants will also have piggy back – registration rights. Upon the closing of the offer to exercise the Company issued New Warrants to purchase 45,000,000 shares of common stock of the Company.

COMMON_STOCK

COMMON STOCK	12 Months Ended
	Dec. 31, 2013
Equity [Abstract]	'
Common Stock Note Disclosure [Text Block]	'
	13	CoMMON STOCK
	The Company is authorized to issue 1,000,000,000 shares of common stock, $0.001 par value. The holders of common stock: (i) have equal rights to dividends from funds legally available therefore, ratably when as and if declared by the Company’s Board of Directors; (ii) are entitled to share ratably in all assets of the Company available for distribution to holders of common stock upon liquidation, dissolution, or winding up of the affairs of the Company; (iii) do not have preemptive, subscription or conversion rights and there are no redemption or sinking fund provisions applicable thereto; (iv) are entitled to one non-cumulative vote per share of common stock, on all matters which shareholders may vote on at all meetings of shareholders; and (v) the holders of common stock have no conversion, preemptive or other subscription rights.  There is no cumulative voting for the election of directors.   Each holder of our common stock is entitled to one vote for each share of our common stock held on all matters submitted to a vote of stockholders. As of December 31, 2013, our Board of Directors had declared no dividends payable to holders of our common stock.
	Common Stock Registration
	On October 3, 2013, the Company filed with the U.S. Securities and Exchange Commission a Form S-1 Registration Statement under the Securities Act of 1933, subsequently amended on December 2, 2013, December 31, 2013 and on January 27, 2014. The purpose of the registration statement was to register 173,333,160 share of common stock for resale by certain investors that are issuable upon conversion of 8% senior convertible debentures and as interest on such debentures and warrants issued by the Company pursuant to a securities purchase agreement entered into between the Company and the certain selling shareholders.
	BBSE Delisting
	On January 17, 2013, the Board of Directors of Amarantus BioScience, Inc. adopted a unanimous written resolution authorizing the Company’s officers, agents, and counsel to take any and all action reasonably necessary to cause the immediate cessation of trading and delisting of Amarantus common stock from the Berlin-Bremen Stock Exchange (the “BBSE”), or from any unofficially regulated markets controlled by the BBSE, including the commencement of legal proceedings in the United States or Germany against the BBSE or any broker or other unauthorized person making a market in the Company’s stock in Germany through the BBSE or otherwise. The Company’s common stock was listed on the BBSE without the Company’s prior knowledge, consent, or authorization. The Company did not authorize or direct any BBSE broker to act as market maker for the Company’s common stock, and believes such listing is part of an organized effort to circumvent U.S. securities laws, including the restrictions against “naked short selling.” The Company’s common stock was delisted from the BBSE on March 19, 2013. The Company believes that de-listing from the BBSE has helped to facilitate orderly trading of the Company’s common stock.
	DTCC Chill
	On April 18, 2013 the Company became aware of a letter dated April 4, 2013 from the Depository Trust Company (“DTC”) indicating that on March 22, 2013, The Depository Trust Company (“DTC”) imposed a restriction on physical deposit and Deposit/Withdrawal At Custodian (“DWAC”) electronic deposit transactions (the “Deposit Chill”) on CUSIP 02300T 109 (the “Issue”), issued by Amarantus Bioscience, Inc. (the “Issuer”). DTC imposed the Deposit Chill in order to prevent additional deposits of the Issue for depository and book-entry transfer services for the reasons set forth below. The letter set forth the concerns of DTC and the procedure the Company must follow in order to object to the imposition of the Deposit Chill. DTC detected various unusually large deposits of shares of predecessor CUSIP 02300Q 105 (the “Predecessor Issue”) during the period from November 21, 2011 to February 1, 2013. More particularly, 234,841,928 shares of the Predecessor Issue and the Issue, representing a substantial percentage of the outstanding float, were deposited at DTC during this period. In order for DTC to make a determination as to whether to lift the Deposit Chill, DTC required that the Company submit a written response (the “Response”) to this notice. The Response must include a legal opinion (“Legal Opinion”), addressed to DTC, in support and confirmation that the Issue satisfies DTC eligibility requirements.
	The Company provided the requested Response to DTC in July of 2013. On July 30, 2013, the Company received notice that The Depository Trust Company has determined to lift the deposit chill (“DTCC Chill”) on the Company’s common stock and has resumed accepting deposits for depository and book-entry transfer services.

STOCK_OPTION_PLAN

STOCK OPTION PLAN	12 Months Ended
	Dec. 31, 2013
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]	'
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	'
	14	Stock option plan
	2008 Stock Plan
	The Company’s Board of Directors approved the 2008 Stock Plan (the “Plan”). Under the Plan, the Company may grant up to 28,242,127 shares of incentive stock options, nonqualified stock options, or stock awards to eligible persons, including employees, nonemployees, members of the Board of Directors, consultants, and other independent advisors who provide services to the Company. In general, options are granted with an exercise price equal to the fair value of the underlying common stock on the date of the grant. Options granted typically have a contractual life of 10 years and vest over periods ranging from being fully vested as of the grant date to four years.
	The following table is a summary of activity under the Plan:
			Common stock options		Weighted Average		Outstanding Options
							Common
							Weighted Average Remaining
			outstanding		Exercise Price		Contractual Term
	Balance – December 31, 2011		9,206,247		0.02		6.4
	Options granted (weighted-average fair value of $0.
	Employee		—		—		—
	Non-Employee		—		—		—
	Options cancelled		—		—		—
	Options Exercised		-7,377,221		0.02		—
	Balance – December 31, 2012		1,829,026		0.02		6.4
	Options granted (weighted-average fair value of $0.52
	Employee		776,924		0.05		9.2
	Non-Employee		5,746,155		0.05		9.2
	Options cancelled		-1,210,817		—		—
	Options Exercised		—		—		—
	Balance – December 31, 2013		6,941,288		0.05		9
	Options vested December 31, 2013		6,891,288
	The amount of awards available to grant under the Plan is 623,618 as of December 31, 2013.
	Title
	2012 Preferred Stock Plan
	In July 2012, our Board of Directors adopted a new stock plan, the Management, Employee, Advisor and Director Preferred Stock Option Plan – 2012 Series B Convertible Preferred Stock Plan (“Preferred Stock Plan”). The purposes of the Preferred Stock Plan are to attract and retain the best available personnel for positions of substantial responsibility, to provide additional incentive to Management, Employees, Advisors and Directors and to promote the success of our business. Certain current and former Management, Employees, Advisors and Directors were awarded a total of 1,248,000 options to purchase Series B Preferred shares on July 15, 2012, and an additional 1,200,000 options on November 4, 2012. These options currently vest over four years and cannot be converted into common shares or sold for two years from the date of the Designation of the Series B Preferred shares. Each share of Series B Preferred stock converts into fifty shares of common stock. The following table is a summary of activity under the Preferred Stock Plan:
			Preferred Stock Options		Weighted Average		Outstanding
							Preferred Options
							Weighted Average Remaining
			Outstanding		Exercise Price		Contractual Term
	Balance – December 31, 2011		—		—		—
	Preferred options granted (weighted-average fair value of $0.0237)
	Employee		2,287,500		0.4742		9.5
	Non-Employee		160,500		0.225		9.8
	Balance – December 31, 2012		2,448,000		0.4578		9.6
	Preferred options cancelled		-160,500		0.225		9.8
	Balance – December 31, 2013		2,287,500		0.4742		8.5
	Preferred options vested at December 31, 2012		1,318,359
	The amount of awards available to grant under the Plan is 712,500 as of December 31, 2013.
	Stock-based compensation expense for all plans for the years ended December 31, and 2013 and 2012, is classified in the statements of operations as follows:
			Year ended			Year ended
			December 31,			December 31,
			2013			2012
	Research and development		$	337,494		$	101,566
	General and administrative			406,195			282,038
	Total		$	743,689		$	383,604
	At December 31, 2013, there was a total of $443,849 of unrecognized compensation cost — net of estimated forfeitures, related to non-vested stock option awards, which is expected to be recognized over a weighted-average period of approximately 2.0 years.
	The fair value of the Company’s stock-based awards during the twelve months ended December 31, 2013 and 2012 were estimated using the following assumptions:
			Year Ended			Year Ended
			December 31,			December 31,
			2013			2012
	Weighted-average volatility		90	%		108	%
	Weighted-average expected term		5			5
	Expected dividends		0	%		0	%
	Risk-free investment rate		2	%		0.5	%
	Expected forfeiture rate		0	%		0	%

INCOME_TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Income Tax Disclosure [Text Block]	'
	15	INCOME TAXES
	There is no provision for income taxes because we have incurred operating losses since inception and applied a full valuation allowance against all deferred tax assets.  The reported amount of income tax expense attributable to operations for the year differs from the amount that would result from applying domestic federal statutory tax rates to loss before income taxes from operations as summarized below:
	Income (Loss) before income taxes		Year ended			Year ended
			December 31, 2013			December 31, 2012
	United States		$	-15,130,681		$	-5,135,618
	Foreign			—			—
	Total Income (Loss) before income taxes		$	-15,130,681		$	-5,135,618
			Year ended December 31, 2013			Year ended December 31, 2012
	Federal tax expense (benefit) at statutory rate		$	-5,144,773		$	-1,746,110
	State tax expense (benefit) net of federal tax effect			-538,715			-298,348
	R&D Credit			-46,000			-19,994
	Non-deductible expenses			2,191,507			88,368
	Change in Valuation Allowance			3,537,981			1,976,084
	Other income			—			—
	Total tax expense		$	—		$	—
	The significant components of deferred tax assets are as follows:
			Year ended December 31, 2013			Year ended December 31, 2012
	Deferred tax assets:
	Net operating loss carry-forward		$	7,317,778		$	4,162,890
	Tax credit carry-forward			203,889			125,954
	Accrued liabilities			722,863			419,704
	Capitalized start-up costs			15,194			15,194
	Depreciation			1,351			1,351
	Gross Deferred Tax Assets			8,263,075			4,725,093
	Valuation Allowance			-8,263,075			-4,725,093
	Net deferred tax assets		$	—		$	—
			December 31, 2013				December 31, 2012
	Federal tax expense (benefit) at statutory rate			34	%			34	%
	State tax expense (benefit) net of federal tax effect			3.6	%			5.8	%
	R&D Credit			0.3	%			0.4	%
	Non-deductible expenses			-14.5	%			-1.7	%
	Change in Valuation Allowance			-23.4	%			-38.5	%
	Total tax expense			—	%			—	%
	The Company’s accounting for deferred taxes involves the evaluation of a number of factors concerning the realizability of the Company’s net deferred tax assets. The Company primarily considered such factors as the Company’s history of operating losses, the nature of the Company’s deferred tax assets and the timing, likelihood and amount, if any, of future taxable income during the periods in which those temporary differences and carryforwards become deductible. At present, the Company does not believe that it is more likely than not that the deferred tax assets will be realized; accordingly, a full valuation allowance has been established and no deferred tax asset is shown in the accompanying balance sheets. The valuation allowance increased by approximately  $3,537,982 and $1,976,084 during the years ended December 31, 2013 and December 31, 2012, respectively.
	As of December 31, 2013, the Company had net federal and state net operating loss carry-forwards of approximately $18,374,939 and $18,378,914, respectively. These net operating loss carry forwards will begin to expire, if not utilized, beginning in 2028 for both federal and state income tax purposes. The Company also has federal and state research and development credit carry-forwards of approximately $133,716 and $140,649, respectively. The federal credits will expire if not utilized beginning in 2029. The California credits do not expire.
	The Tax Reform Act of 1986 and similar California legislation impose substantial restrictions on the use of net operating losses and tax credits in the event of an ownership change of a corporation. Accordingly, the Company’s ability to use net operating losses and credit carry forwards may be significantly limited in the future as a result of such an ownership change.
	On January 1, 2009, the Company adopted a newly issued standard of accounting for uncertain tax positions. This standard prescribes a comprehensive model for the recognition, measurement, presentation and disclosure in financial statements of any uncertain tax positions that have been taken or expected to be taken on a tax return. The cumulative effect of adopting the new standard resulted in no adjustment to retained earnings as of January 1, 2009. No liability related to uncertain tax positions is recorded on the financial statements. It is the Company’s policy to include penalties and interest expense related to income taxes as a component of tax expense, as necessary.
	Beginning balance January 1, 2011		$	12,391
	Increase/(decrease) of unrecognized tax benefits taken in prior years			—
	Increase/(decrease) of unrecognized tax benefits related to current year			4,558
	Increase/(decrease) of unrecognized tax benefits related to settlements			—
	Reductions to unrecognized tax benefits related lapsing statute of limitations			—
	Ending balance at December 31, 2012		$	16,949
	Increase/(decrease) of unrecognized tax benefits taken in prior years
	Increase/(decrease) of unrecognized tax benefits related to current year			10,487
	Increase/(decrease) of unrecognized tax benefits related to settlements			—
	Reductions to unrecognized tax benefits related lapsing statute of limitations			—
	Ending balance at December 31, 2013		$	27,436
	The total amount of unrecognized tax benefits that if recognized, would affect the effective tax rate is $0.
	The Company has not incurred any interest or penalties as of December 31, 2013. The Company does not anticipate any significant change within 12 months of this reporting date of its uncertain tax positions. The Company is subject to taxation in the US and California. There are no ongoing examinations by taxing authorities at this time.
	The Company’s tax years 2008 through 2013 will remain open for examination by the federal and state authorities for 3 and 4 years, respectively, from the date of utilization of any net operating loss credits.

RELATEDPARTY_TRANSACTIONS

RELATED-PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2013
Related Party Transactions [Abstract]	'
Related Party Transactions Disclosure [Text Block]	'
		16	RELATED-PARTY TRANSACTIONS
	Acquisition of MANF and associated obligations
	The Company was co-founded in 2008 by Mr. Gerald Commissiong and Dr. John Commissiong under the original name of CNS Protein Therapeutics, Inc. (“CNS”), and changed its name to Amarantus Bioscience, Inc. in 2010, and now Amarantus Bioscience Holdings, Inc. Dr. Commisiong is currently the Chief Scientific Officer, a member of the Board of Directors (appointed in March 2011) and majority shareholder of the Company. Mr. Gerald Commissiong is currently the Chief Executive Officer, a member of the Board of Directors, and a significant shareholder of the Company. Dr. Commissiong also founded Neurotrophics, Inc., a Canadian company, in 2003. In 2007, Neurotrophics established an agreement with EMS Development Group to acquire the intellectual property rights to a protein compound, mesencephalic astrocyte-derived neurotrophic factor (“MANF”), from Prescient Neuropharma Co. MANF was discovered by Dr. Commissiong while working for Prescient in 2002, as a drug candidate with promising therapeutic properties for treatment of syndromes such Parkinson’s Disease.
	EMS received $59,000 in 2007 in funding from Neurotrophics to purchase the MANF intellectual property rights. Prior to this payment, Neurotrophics received a total of $100,000 in investments from certain outside parties. The same investors provided $100,000 in funding to CNS in 2008, and CNS renegotiated and assumed the $100,000 convertible note investment made into Neurotrophics. The investors directed Neurotrophics and EMS to assign the MANF intellectual property rights to CNS and CNS agreed to assume certain other liabilities related to the technology transfer. CNS will compensate these creditors on a future date mutually agreeable between the parties. In addition, CNS agreed to compensate EMS for its assistance in acquiring the rights to MANF by making installment payments in an aggregate amount of $95,000.
	The technology transfer transaction created a contingent liability for the Company. Legal counsel to the Company has advised that transfers of assets out of the usual course of business, referred to under applicable Canadian law as “bulk sales”, must comply with certain rules in order to avoid a potential voiding of the sale or transfer, making the purchaser liable to unpaid trade creditors, or creating an encumbrance on the assets transferred or sold. The transfer of the MANF rights by Neurotrophics to CNS may impose such obligations on CNS, as a purchaser. Counsel further advised that upon payment in full of all of the Neurotrophics debts outstanding as of March 5, 2008, no action can be successfully maintained to void or set aside the transfer of the MANF rights to CNS, and thus to the Company.
	To remedy this contingent liability, CNS agreed to compensate Neurotrophics to repay its creditors on a future date mutually agreeable between the parties, and agreed to assume debts owed to John Commissiong and Gerald Commissiong by Neurotrophics.
	The Company has recorded a total of $0 and $0 as of December 31, 2013 and 2012, respectively in obligations reflecting this liability in its financial statements. The Company recorded the assumption of the Neurotrophics debts as a distribution in 2008.
	Royalty Agreement - Founders
	In October 2010, the Company entered into an agreement with the founders, Gerald Commissiong and John Commissiong, where they will receive a 2.5% (1.25% each for Gerald Commissiong and John Commissiong) Royalty from the gross commercial revenue of patents derived from the Company’s proprietary PhenoGuard platform technology, including patents associated with the MANF Protein and related Gene." To date no payments have been made.
	Former Chairman
	The Company obtained the services of its former Chairman Martin D. Cleary through a consulting agreement. During the years ended December 31, 2013, 2012, and the period from January 14, 2008 (date of inception) to December 31, 2013, consulting services of $0, $0, and $479,166, respectively are included in the statement of operations. This agreement also includes a change of control clause whereby the Company shall pay Mr. Cleary a bonus of 5% of the gross proceeds to the Company resulting from the change of control. Upon his election and in his sole discretion, and in lieu of the change of control bonus, the Company shall issue to him shares of the Company’s common stock equal to 2.5% of the Company’s fully diluted capitalization as of the date of termination of the agreement. Mr. Cleary resigned from the Company in July, 2012.
	Related Party Capital Transactions
	In March 2012, a former and an existing Board of Director member converted a Convertible Promissory Note in the amount of $21,000, each plus accrued interest. This resulted in the issuance of 217,280 shares of Common Stock to each party. In addition, in March 2012 an existing Board of Director member converted a Convertible Promissory Note in the amount of $30,000. This resulted in the issuance of 608,300 shares of Common Stock. The same Board member also holds $60,172 of Convertible Promissory Note with the company as of December 31, 2013. $100,000 of this Convertible Promissory Note was converted in January 2013, resulting in the issuance of 2,765,625 shares of Common Stock. The same Board member also holds $5,556 8% Senior convertible debentures.
	Related Party Debt transactions
	In October 2013, the Company’s Chief Executive Officer, Gerald Commissiong, its Chief Scientific Officer, John Commissiong and one of the Company’s Directors Robert Harris invested $5,000 each or an aggregate of $15,000 in the Debenture and Warrant Transaction (see Note 9) and was each issued a Denture in the principal aggregate amount of $5,556 and a warrant to purchase 138,889 shares. The shares underlying the Debentures and Warrants purchased by Messrs. Gerald Commissiong, John Commissiong and Robert Harris were not included in the related registration statement.

SUBSEQUENT_EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2013
Subsequent Events [Abstract]	'
Subsequent Events [Text Block]	'
	17	SUBSEQUENT EVENTS
	The Company evaluated subsequent events through the date that its financial statements were available for issuance on April 21, 2014.
	Eltoprazine In-License Agreement
	Effective January 14, 2014, the “Company entered into a License Agreement (the “License Agreement”) with PGI Drug Discovery, LLC (“PGI”), pursuant to which the Company was granted an exclusive license (with a right to sublicense) to utilize certain Licensed Compounds and Licensed Products (as each is defined in the License Agreement) of PGI, which includes certain intellectual property covering the use of Eltoprazine and certain of its related compounds in all therapeutic indications (“Eltoprazine”), as further described in the License Agreement).
	Pursuant to the terms of the License Agreement, the Company has agreed to: (i) pay PGI $100,000 in cash for the License within 20 days of the execution of the License Agreement, (ii) pay PGI up to an aggregate of $4 million in development milestones through NDA submission, (iii) pay a research support payment to PGI as partial reimbursement for costs incurred for earlier research and management of CIAS, ADHD and levodopa induced dyskinesia (LID) clinical trials totaling up to $650,000 to be paid in a mixture of cash and stock, and (iv) reimburse PGI for the Eltoprazine clinical supply inventory up to $500,000 payable upon the earlier of the initiation of a Phase IIb clinical study or 6 months after the date of the License Agreement. As further consideration for the License Agreement, the Company shall pay a single digit royalty to PGI of the annual worldwide aggregate net sales by the Company.
	Simultaneous with the execution of the License Agreement, the Company and PGI entered into a Services Agreement pursuant to which PGI will provide certain services to the Company related to PGI’s proprietary analytical systems as will be set forth in certain study plans. The Company agreed to a payment commitment of $450,000 at a minimum annual rate of $150,000 for each of three years. The Services Agreement is for a term of the later of 3 years or the completion of any study plan accepted by the parties under the Services Agreement.
	As partial consideration of the research support payment by the Company to PGI, the Company entered into a Securities Purchase Agreement with PGI, pursuant to which PGI subscribed for 4,000,000 shares of the Company’s common stock. In connection with the 4,000,000 shares, the Company granted PGI certain piggy-back registration rights.
	MANF In-License Option Agreement
	On February 28, 2014, the “Company entered into an Option Agreement (the “Agreement”) with the University of Massachusetts (“UMass”) pursuant to which the Company was granted an option to obtain an exclusive license (with the right to sublicense) in the patent applications to be filed based upon UMA 14-006 titled “MANF as a Therapeutic Agent for the production of Mammalian Sensory Cells”. The term of the option is 18 months, which may be extended by the Company for an additional six months upon demonstration to UMass of continued progress evaluating the business opportunity with respect to the patent rights and payment of a fee to the University. In consideration for the grant of the option, the Company paid an option fee of $1,000 and shall pay a retainer fee of $15,000 to cover initial patent expenses to be incurred in connection with obtaining the patent rights.
	Common Stock Purchase Agreement
	On March 7, 2014,  the “Company signed a $20 million purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), an Illinois limited liability company. Upon signing the purchase agreement LPC agreed to purchase 4,000,000 shares of our common stock for $400,000 as an initial purchase under the agreement. We also entered into a registration rights agreement with LPC whereby we agreed to file a registration statement related to the transaction with the SEC covering the shares that may be issued to LPC under the purchase agreement within ten days after the date the Company files with the SEC its annual report on Form 10-K for the fiscal year ended December 31, 2013. After the SEC has declared effective the registration statement related to the transaction, we have the right, in our sole discretion, over a 30-month period to sell up to an additional $19.6 million of our common stock to LPC in amounts up to $500,000 per sale, depending on certain conditions as set forth in the purchase agreement. There are no upper limits to the price LPC may pay to purchase our common stock and the purchase price of shares of Common Stock sold pursuant to the Purchase Agreement will be based on prevailing market prices of our Common Stock at the time of sales without any fixed discount, and the Company will control the timing and amount of any sales of Common Stock to LPC. In addition, the Company may direct LPC to purchase additional amounts as accelerated purchases if on the date of a regular purchase the closing sale price of the Common Stock is not below the threshold price as set forth in the Purchase Agreement. LPC shall not have the right or the obligation to purchase any shares of our common stock on any business day that the price of our common stock is below the floor price as set forth in the Purchase Agreement.
	The Purchase Agreement contains customary representations, warranties, covenants, closing conditions and indemnification and termination provisions by, among and for the benefit of the parties. LPC has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of the Company’s shares of common stock. In consideration for entering into the $20 million agreement, we issued to LPC 6,000,000 shares of our common stock and may issue up to an additional 3,500,000 shares pro rata if and when we sell to LPC up to an additional $19.6 million of our common stock. The agreement may be terminated by us at any time at our discretion without any monetary cost to us. Actual sales of shares of Common Stock to LPC under the agreement will depend on a variety of factors to be determined by the Company from time to time, including (among others) market conditions, the trading price of the Common Stock and determinations by the Company as to available and appropriate sources of funding for the Company and its operations. The proceeds received by the Company under the agreement are expected to be used for product development, commercialization, strategic acquisitions, and general corporate purposes.
	If the registration statement at any time ceases to be effective or if the Investors are not permitted to utilize the prospectus related to the registration statement to resell securities intended to be registered therein for more than 10 consecutive calendar days or for more than an aggregate of 15 calendar days during any twelve month period, then the Company is obligated to pay the affected Investors an amount in cash, as partial liquidated damages, equal to 2% multiplied by the aggregate subscription amount paid by the Investors each month until such condition is cured, plus interest if any such liquidated damages are paid beyond a specified payment date as provided for in the agreement.
	Demand Promissory Note Payable Term Extension
	On March 12, 2014, the Company opted to extend the maturity date of the $500,000 Demand Promissory Note issued to Dominion Capital LLC on February 14, 2014 to August 14, 2014.
	Appointment of the Company’s New Chief Financial Officer
	On April 1, 2014, Amarantus Bioscience Holdings, Inc., a Nevada corporation (the “Company”) appointed Robert Farrell, J.D. to serve as the Company’s Chief Financial Officer (the “CFO”). Mr. Marc Faerber will now serve as the Company’s Corporate Controller and Vice President of Financial Operations.
	Mr. Farrell served as Chief Financial Officer of Titan Pharmaceuticals from 1996 to 2008, and as President and CEO from 2008 to 2010. During his tenure at Titan Mr. Farrell was responsible for all SEC filings, fund raising, financial and tax planning strategies, mergers & acquisitions, corporate partnerships, licensing transactions and financial operations. Mr. Farrell most recently served as CFO at Sanovas, Inc. Mr. Farrell previously served as CFO, Corporate Group Vice President and General Counsel at Fresenius USA and Fresenius Medical Care. Mr. Farrell also previously served as the CFO for the Institute for One World Health in San Francisco and currently serves on the Board of Directors of Prime Genomics, Inc. Mr. Farrell holds a J.D. from the University of California's Hastings School of Law.
	Mr. Farrell will initially be engaged as a contract consultant but is expected to be a full-time employee by the end of April 2014 upon execution of an employment agreement.

DEVELOPMENT_STAGE_AND_GOING_CO1

DEVELOPMENT STAGE AND GOING CONCERN (Policies)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Consolidation, Policy [Policy Text Block]	'
	Principles of Consolidation - The Consolidated Financial Statements include the accounts of Amarantus BioScience Holdings, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	'
	Use of Estimates - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
Certain Significant Risks And Uncertainties [Policy Text Block]	'
	Certain Significant Risks and Uncertainties - The Company participates in a global, dynamic, and highly competitive industry and believes that changes in any of the following areas could have a material adverse effect on the Company’s future financial position, results of operations, or cash flows: ability to obtain future financing; advances and trends in new technologies and industry standards; regulatory approval and market acceptance of the Company’s products; development of the necessary manufacturing capabilities and the Company’s ability to obtain adequate resources of necessary materials; development of sales channels; certain strategic relationships; litigation or claims against the Company based on intellectual property, patent, product, regulatory, or other factors; and the Company’s ability to attract and retain employees and other resources necessary to support its growth.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	'
	Concentration of Credit Risk - Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash and cash equivalents. The Company places its cash and cash equivalents with domestic financial institutions that are federally insured within statutory limits.
Cash and Cash Equivalents, Policy [Policy Text Block]	'
	Cash and Cash Equivalents - The Company considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block]	'
	Intangible Assets – Intangible assets or certain rights to use certain intangible assets for the Company’s research and development activities are capitalized as assets in cases where the Company has determined that those assets have an identifiable alternative future use in accordance with US GAAP. If the Company concludes that those assets have useful lives that are indeterminable then they are assumed to be indefinite lived unless. In 2013 the Company determined that the useful lives of those assets can be reasonable estimated and in which case those assets are being amortized to expense over their estimated useful lives of between 10.9 years and 18.5 years depending on the patent expire date.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	'
	Impairment of Long-Lived Assets- The Company reviews the carrying value of long-lived assets, including intangible assets and property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying value may not be fully recoverable. There have been no impairments for the years ended December 31, 2013 and 2012.
	Restatement of Prior Quarters
	In the fourth quarter of 2013, we discovered that some of the amounts we had previously reported in prior quarters had not been recorded correctly. The adjustments to correct for accounting differences were made in the fourth quarter of 2013 and are primarily related to our accounting for convertible note obligations.
	The following table sets forth the effects of the restatement on affected items within our previously reported Consolidated Balance Sheets for the periods ended March 31, 2013, June 30, 2013 and September 30, 2013 had the adjustments been made in the corresponding quarters.
		March 31, 2013				June 30, 2013				September 30, 2013
		As Reported		As Restated		As Reported		As Restated		As Reported		As Restated
	Derivative liabilities		921,954		794,468		250,011		419,239		1,544,443		2,427,367
	Convertible promissory notes		328,727		328,726		674,161		631,961		485,936		475,780
	Total Liabilities		6,165,888		6,038,401		5,576,483		5,703,511		4,664,706		5,537,474
	Additional paid in capital		9,367,041		11.274,893		10,728,916		12,678,967		13,760,385		16,053,726
	Deficit accumulated during the development stage		-14,719,336		-16,499,701		-15,620,221		-17,697,300		-17,645,773		-20,737,511
	Stockholder’s deficit	$	-4,967,128	$	-4,839,641	$	-4,449,302	$	-4,576,330	$	-3,354,569	$	-4,152,966
	The following table sets forth the effects of the restatement on affected items within our previously reported Consolidated Statement of Operations for the three months ended March 31, 2013, June 30, 2013 and September 30, 2013 had the adjustments been made in the corresponding quarters.
		March 31, 2013				June 30, 2013				September 30, 2013
		As Reported		As Restated		As Reported		As Restated		As Reported		As Restated
	Operating loss	$	-1,884,597	$	-1,884,597	$	-1,304,475	$	-1,304,475	$	-678,548	$	-678,548
	Non-operating income (loss)		-972,691		-2,753,056		403,590		106,876		-1,346,964		-2,361,623
	Net loss		-2,857,288		-4,637,653		-900,885		-1,197,599		-2,025,512		-3,040,171
	Net loss per common share, basic and diluted	$	-0.01	$	-0.01	$	0	$	0	$	0	$	-0.01
	The following table sets forth the effects of the restatement on affected items within our previously reported Consolidated Statement of Operations for the six and nine months ended June 30, 2013 and September 30, 2013, respectively had the adjustments been made in the corresponding quarters.
		June 30, 2013				September 30, 2013
		As Reported		As Restated		As Reported		As Restated
	Operating loss	$	-3,189,072	$	-3,189,072	$	-3,867,619	$	-3,867,619
	Non-operating loss		-569,101		-2,646,180		-1,916,066		-5,007,804
	Net Loss	$	-3,758,173	$	-5,835,252	$	-5,783,685	$	-8,875,423
	Net loss per common share, basic and diluted	$	-0.01	$	-0.01	$	-0.01	$	-0.02
Revenue Recognition, Policy [Policy Text Block]	'
	Revenue Recognition - The Company recognizes revenue when the earnings process is complete, when revenue is realized or realizable and earned, when persuasive evidence a revenue arrangement exists, delivery of goods or services has occurred, the sales price is fixed or determinable, and collectability is reasonably assured.
	The Company accounts for milestones related to research and development activities in accordance with the milestone method of revenue recognition of Accounting Standards Codification Topic 605-28, under which consideration contingent on the achievement of a substantive milestone is recognized in its entirety in the period when the milestone is achieved. A milestone is considered to be substantive when it meets all of the following criteria: the milestone is commensurate with either the performance required to achieve the milestone or the enhancement of the value of the delivered items resulting from the performance required to achieve the milestone; the milestone relates solely to past performance; and, the milestone is reasonable relative to all of the deliverables and payment terms within the agreement.
	To date, the Company has only received research grant revenue and contract revenue. Research grant revenue and contract revenue is recognized as the Company provides the services stipulated in the underlying agreement based on the time and expenditures incurred, and all terms required in the agreement have been met.  Amounts received in advance of services provided are recorded as deferred revenue and amortized as revenue when the services are provided.
Research and Development Expense, Policy [Policy Text Block]	'
	Research and Development Expenditures - Research and development expenses consist of personnel costs, including salaries, benefits and stock-based compensation, materials and supplies, licenses and fees, and overhead allocations consisting of various administrative and facilities related costs. Research and development activities are also separated into three main categories: research, clinical development, and biotechnology development. Research costs typically consist of preclinical and toxicology costs. Clinical development costs include costs for Phase 1 and 2 clinical studies. Biotechnology development costs consist of expenses incurred in connection with product formulation and analysis. The Company charges research and development costs, including clinical study costs, to expense when incurred.
Fair Value of Financial Instruments, Policy [Policy Text Block]	'
	Fair Value of Financial Instruments - The fair value of certain of the Company’s financial instruments, including cash and cash equivalents, accrued compensation, and other accrued liabilities, approximate cost because of their short maturities. The Company measures the fair value of certain of its financial assets and liabilities on a recurring basis. A fair value hierarchy is used to rank the quality and reliability of the information used to determine fair values. Financial assets and liabilities carried at fair value will be classified and disclosed in one of the following three categories:
	•   Level 1-Quoted prices (unadjusted) in active markets for identical assets and liabilities.
	•   Level 2-Inputs other than Level 1 that are observable, either directly or indirectly, such as unadjusted quoted prices for similar assets and liabilities, unadjusted quoted prices in the markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	•   Level 3-Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	'
	Stock-Based Compensation - Stock-based compensation is measured at the grant date based on the fair value of the award. The fair value of the award that is ultimately expected to vest is recognized as expense on a straight-line basis over the requisite service period, which is generally the vesting period. The expense recognized for the portion of the award that is expected to vest has been reduced by an estimated forfeiture rate. The forfeiture rate is determined at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
	Expected Term — The expected term of options represents the period that the Company’s stock-based awards are expected to be outstanding based on the simplified method, which is the half-life from vesting to the end of its contractual term.
	Expected Volatility — The Company computes stock price volatility over expected terms based on its historical common stock trading prices.
	Risk-Free Interest Rate — The Company bases the risk-free interest rate on the implied yield available on U.S. Treasury zero-coupon issues with an equivalent remaining term.
	Expected Dividend — The Company has never declared or paid any cash dividends on its common shares and does not plan to pay cash dividends in the foreseeable future, and, therefore, uses an expected dividend yield of zero in its valuation models. The Company recognizes fair value of stock options granted to nonemployees as stock-based compensation expense over the period in which the related services are received.
Stockholders Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]	'
	Preferred Stock - Preferred shares subject to mandatory redemption (if any) are classified as liability instruments and are measured at fair value. The Company classifies conditionally redeemable preferred shares, which includes preferred shares that feature redemption rights that are either within the control of the holder or subject to redemption upon the occurrence of uncertain events not solely within the Company’s control, as temporary equity. At all other times, the Company classifies its preferred shares in stockholders’ deficiency.
Convertible Instruments [Policy Text Block]	'
	Convertible Instruments – The Company bifurcates conversion options from their host instruments and account for them as free standing derivative financial instruments if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable generally accepted accounting principles with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. An exception to this rule is when the host instrument is deemed to be conventional, as that term is described under applicable GAAP.
	When the Company has determined that the embedded conversion options should not be bifurcated from their host instruments, the Company records, when necessary, discounts to convertible notes for the intrinsic value of conversion options embedded in debt instruments based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized over the term of the related debt to their stated date of redemption. The Company also records, when necessary, deemed dividends for the intrinsic value of conversion options embedded in preferred shares based upon the differences between the fair value of the underlying common stock at the commitment date of the transaction and the effective conversion price embedded in the preferred shares.
Common Stock Purchase Warrants And Derivative Financial Instruments [Policy Text Block]	'
	Common Stock Purchase Warrants and Derivative Financial Instruments - The Company classifies all of its common stock purchase warrants and other derivative financial instruments as equity if the contracts (1) require physical settlement or net-share settlement or (2) give the Company a choice of net-cash settlement or settlement in its own shares (physical settlement or net-share settlement). The Company classifies as assets or liabilities any contracts that (1) require net-cash settlement (including a requirement to net cash settle the contract if an event occurs and if that event is outside the control of the Company), (2) give the counterparty a choice of net-cash settlement or settlement in shares (physical settlement or net-share settlement), or (3) that contain reset provisions. The Company assesses classification of its common stock purchase warrants and other derivatives at each reporting date to determine whether a change in classification between assets and liabilities is required.
Debt, Policy [Policy Text Block]	'
	Debt Discounts - The Company records, as a discount to notes and convertible notes, the relative fair value of warrants issued in connection with the issuances and the intrinsic value of any conversion options based upon the differences between the fair value of the underlying common stock at the commitment date of the note transaction and the effective conversion price embedded in the note. Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption.
Income Tax, Policy [Policy Text Block]	'
	Income Taxes - The Company accounts for income taxes using the liability method whereby deferred tax asset and liability account balances are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company provides a valuation allowance, if necessary, to reduce deferred tax assets to their estimated realizable value.
	In evaluating the ability to recover its deferred income tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning, and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. In the event the Company determines that it would be able to realize its deferred income tax assets in the future in excess of their net recorded amount, it would make an adjustment to the valuation allowance that would reduce the provision for income taxes. Conversely, in the event that all or part of the net deferred tax assets are determined not to be realizable in the future, an adjustment to the valuation allowance would be charged to earnings in the period such determination is made.
	The Company recognizes the tax benefit from uncertain tax positions in accordance with GAAP, which prescribes a recognition threshold and measurement, attribute for the financial statement recognition and measurement of uncertain tax positions taken or expected to be taken in a company’s tax return.
Earnings Per Share [Policy Text Block]	'
	Net Loss Per Common Shareholder - Basic net loss per share is based upon the weighted average number of common shares outstanding. Diluted net loss per share is based on the assumption that all dilutive convertible shares and stock options were converted or exercised. Dilution is computed by applying the treasury stock method. Under this method, options, warrants and restricted stock are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period.
New Accounting Pronouncements, Policy [Policy Text Block]	'
	Recently Issued Accounting Pronouncements
	In July 2013, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2013-11, “Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”, or ASU No. 2013-11, which concludes that, under certain circumstances, unrecognized tax benefits should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward. ASU No. 2013-11 will be effective for us beginning January 1, 2014. We do not anticipate that the adoption of this standard will have a material impact on our financial position or results of operations.
Compensation Related Costs, Policy [Policy Text Block]	'
	Executive Compensation
	Unpaid bonuses to Gerald E. Commissiong, President and Chief Executive Officer and Dr. John W. Commissiong, Chief Scientific, Officer, were improperly reflected as prepaid expenses and other current assets in form 10-K filed with the Security and Exchange Commission on 4/17/2013, and forms 10-Q filed with the Security and Exchange Commission on 5/12/2013, 8/19/2013 and 11/14/2013. This improper classification was not in conformity with the financial policies of the Company. In the fourth quarter 2013 were paid and thereby eliminating this improper classification. A total bonus of $443,874 was paid in 2014, $230,222 for Gerald E. Commissiong, and $213,763 for Dr. John W. Commissiong

DEVELOPMENT_STAGE_AND_GOING_CO2

DEVELOPMENT STAGE AND GOING CONCERN (Tables)	12 Months Ended
	Dec. 31, 2013
Accounting Policies [Abstract]	'
Restatement Of Prior Year Balance Sheets [Table Text Block]	'
	The following table sets forth the effects of the restatement on affected items within our previously reported Consolidated Balance Sheets for the periods ended March 31, 2013, June 30, 2013 and September 30, 2013 had the adjustments been made in the corresponding quarters.
		March 31, 2013				June 30, 2013				September 30, 2013
		As Reported		As Restated		As Reported		As Restated		As Reported		As Restated
	Derivative liabilities		921,954		794,468		250,011		419,239		1,544,443		2,427,367
	Convertible promissory notes		328,727		328,726		674,161		631,961		485,936		475,780
	Total Liabilities		6,165,888		6,038,401		5,576,483		5,703,511		4,664,706		5,537,474
	Additional paid in capital		9,367,041		11.274,893		10,728,916		12,678,967		13,760,385		16,053,726
	Deficit accumulated during the development stage		-14,719,336		-16,499,701		-15,620,221		-17,697,300		-17,645,773		-20,737,511
	Stockholder’s deficit	$	-4,967,128	$	-4,839,641	$	-4,449,302	$	-4,576,330	$	-3,354,569	$	-4,152,966
Restatement to Prior Year Income [Table Text Block]	'
	The following table sets forth the effects of the restatement on affected items within our previously reported Consolidated Statement of Operations for the three months ended March 31, 2013, June 30, 2013 and September 30, 2013 had the adjustments been made in the corresponding quarters.
		March 31, 2013				June 30, 2013				September 30, 2013
		As Reported		As Restated		As Reported		As Restated		As Reported		As Restated
	Operating loss	$	-1,884,597	$	-1,884,597	$	-1,304,475	$	-1,304,475	$	-678,548	$	-678,548
	Non-operating income (loss)		-972,691		-2,753,056		403,590		106,876		-1,346,964		-2,361,623
	Net loss		-2,857,288		-4,637,653		-900,885		-1,197,599		-2,025,512		-3,040,171
	Net loss per common share, basic and diluted	$	-0.01	$	-0.01	$	0	$	0	$	0	$	-0.01
	The following table sets forth the effects of the restatement on affected items within our previously reported Consolidated Statement of Operations for the six and nine months ended June 30, 2013 and September 30, 2013, respectively had the adjustments been made in the corresponding quarters.
		June 30, 2013				September 30, 2013
		As Reported		As Restated		As Reported		As Restated
	Operating loss	$	-3,189,072	$	-3,189,072	$	-3,867,619	$	-3,867,619
	Non-operating loss		-569,101		-2,646,180		-1,916,066		-5,007,804
	Net Loss	$	-3,758,173	$	-5,835,252	$	-5,783,685	$	-8,875,423
	Net loss per common share, basic and diluted	$	-0.01	$	-0.01	$	-0.01	$	-0.02

BALANCE_SHEET_DETAILS_Tables

BALANCE SHEET DETAILS (Tables)	12 Months Ended
	Dec. 31, 2013
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Schedule Of Balance Sheet Details [Table Text Block]	'
	Prepaid expenses and other current assets:
		Year Ended December 31,
		2013		2012
	Prepaid expenses	$	91,853	$	409,710
	Deferred financing costs		109,233		46,909
	Other		14,100		64,001
	Total	$	215,186	$	520,620
	Accrued liabilities:
		Year Ended December 31,
		2013		2012
	Accrued compensation and related benefits	$	266,407	$	18,746
	Series D Convertible Preferred dividend		25,987		—
	Total	$	292,394	$	18,746
	Related party liabilities:
		Year Ended December 31,
		2013		2012
	Promissory note	$	222,083	$	222,083
	Accrued interest		25,884		21,442
	Total	$	247,967	$	243,525

FAIR_VALUE_MEASUREMENTS_Tables

FAIR VALUE MEASUREMENTS (Tables)	12 Months Ended
	Dec. 31, 2013
Fair Value Disclosures [Abstract]	'
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	'
	The Company’s financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2013 and 2012, by level within the fair value hierarchy, are as follows:
	Fair Value Measurements at December 31, 2013
		Level 1			Level 2		Level 3		Total
	Warrant liability	$	—		$	—	$	—	$	—
	Derivative Liability		—			—		5,859,170		5,859,170
	Total fair value	$	—		$	—	$	5,859,170	$	5,859,170
	Fair Value Measurements at December 31, 2012
		Level 1			Level 2		Level 3		Total
	Warrant liability	$	—		$	—	$	232,988	$	232,988
	Derivative Liability		—			—		26,893		26,893
	Total fair value	$	—		$	—	$	259,881	$	259,881
Summary of Changes in the Fair value of the Companys Level 3 Financial Liability [Table Text Block]	'
	The following table provides a summary of changes in the fair value of the Company’s Level 3 financial liabilities from January 1, 2012 to December 31, 2013:
			Warrant Liability		Derivative Liability		Total
	31-Dec-11		283,931			140,706		424,637
	Conversion of warrants to common stock		-2,031			—		-2,031
	Issuance of convertible notes		—			4,044,349		4,044,349
	Change in fair value		-48,912			-4,158,162		-4,207,074
	31-Dec-12		232,988			26,893		259,881
	Issuance of convertible notes		—			8,582,295		8,582,295
	Reclass to additional paid in capital		—			-2,711,816		-2,711,816
	Change in fair value		-232,988			-38,202		-271,190
	31-Dec-13		—		$	5,859,170	$	5,859,170
Fair Value, Concentration of Risk [Table Text Block]	'
	The fair value of the warrants at December 31, 2013 and 2012 were determined using the Black-Scholes model with the following assumptions:
		2013		2012
	Annualized volatility	331% - 335%		275% - 624%
	Contractual life (years)	0.04		0.5
	Expected dividends	0%		0%
	Risk-free investment rate	0.62 - 0.91%		0.12 - .014%

NET_LOSS_PER_SHARE_Tables

NET LOSS PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2013
Earnings Per Share [Abstract]	'
Schedule Of Net Income Loss Per Share [Table Text Block]	'
	The following table sets forth the computation of the basic and diluted net loss per share attributable to Amarantus common stockholders for the periods indicated:
			Year Ended December 31,
			2013			2012
	Numerator
	Net Loss		$	-15,131,681		$	-5,135,618
	Preferred stock dividend			38,402			—
	Net loss applicable to common stockholders		$	-15,170,083		$	-5,135,618
	Denominator
	Weighted average shares outstanding during the period:
	Common stock - basic			450,931,510			140,710,454
	Common shares equivalents			—			—
	Common stock - diluted			450,931,510			140,710,454
	Net loss per share		$	-0.03		$	-0.04
	Potentially dilutive securities:
	Outstanding time-based common stock options(1)		6,941,000		-	-2
	Outstanding time-based preferred stock options(1)		2,288,000		-	-2
	Warrants(1)		84,553,000		-	-2
	Relating party liabilities		3,107,000		-	-2
	Convertible promissory note(s)(1)		6,325,000		-	-2
	8% Senior convertible debentures		75,000,000		-	-2
	Convertible preferred stock(1) (3)		753,000		-	-2
	-1	The impact of time-based stock options, warrants, the convertible notes and the convertible preferred stock on earnings per share is anti-dilutive in a period of loss from continuing operations.
	-2	Total anti dilutive securities in 2012 was approximately 84,000,000.
	-3	Includes Series C and D Convertible Preferred Stock.

INTANGIBLE_ASSETS_Tables

INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]	'
Schedule of Indefinite-Lived Intangible Assets [Table Text Block]	'
	The following table summarizes our intangible assets:
		Year Ended December 31,
		2013		2012
	Intangible assets:
	License – Power 3 Medical	$	430,252	$	484,643
	License – Memory Dx (LymPro)		145,940	$	47,500
	License – University of Massachusetts		34,902		—
	Total intangible assets net	$	611,094	$	532,143
Finite-lived Intangible Assets Amortization Expense [Table Text Block]	'
	Amortizable intangible assets as of December 31, 2013 and 2012 consist of the following:
		December 31, 2013
		Gross		Accumulated		Net Book
		Carrying		Amortization		Value
		Amount
	License costs		681,143		-70,049		611,094
		December 31, 2012
		Gross		Accumulated		Net Book
		Carrying		Amortization		Value
		Amount
	License costs	$	532,143	$	—	$	532,143
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	'
	As of December 31, 2013, amortization expense for the next five years is expected to be as follows:
	2014	$	44,599
	2015		44,599
	2016		44,721
	2017		44,599
	2018		44,599
	thereafter		387,977
	Total	$	611,094

CONVERTIBLE_NOTES_PAYABLE_Tabl

CONVERTIBLE NOTES PAYABLE (Tables) (Convertible Notes Payable [Member])	12 Months Ended
	Dec. 31, 2013
Convertible Notes Payable [Member]	'
Schedule of Debt [Table Text Block]	'
	The following table summarizes the Company’s outstanding convertible notes payable obligations:
							Principal Balance Outstanding
	Issue Date	Maturity Date	Stated			Conversion Terms	December 31,		December 31,
			Interest Rate				2013		2012
	11/14/12	6/3/13		10	%	Fixed at $0.10	$	0	$	600,000
	10/4/11	9/6/14		20	%	$0.05 subject to adjustments		0		140,000
						Notes payable, current	$	0	$	740,000

8_SENIOR_CONVERTIBLE_DEBENTURE1

8% SENIOR CONVERTIBLE DEBENTURES (Tables) (8% Senior Convertible Debentures [Member])	12 Months Ended
	Dec. 31, 2013
8% Senior Convertible Debentures [Member]	'
Schedule of Debt [Table Text Block]	'
	The following table summarizes the Company’s outstanding 8% convertible promissory note obligations:
						Principal Balance Outstanding
	Issue Date	Maturity	Stated		Conversion Terms	December 31, 2013		December 31,
		Date	Interest					2012
			Rate
	10/2/13	10/2/14	8	%	Variable conversion price	$	1,788,889	$	0
	-0.000745156	9/6/14	8	%	Variable conversion price		1,544,443		-0-
		Sub total					3,333,332		0
		Discount on convertible promissory notes					-2,401,390		-0-
		Current portion of 8% convertible promissory notes, net				$	931,942	$	0

CONVERTIBLE_PROMISSORY_NOTES_T

CONVERTIBLE PROMISSORY NOTES (Tables) (Convertible Promissory Notes Payable [Member])	12 Months Ended
	Dec. 31, 2013
Convertible Promissory Notes Payable [Member]	'
Schedule of Debt [Table Text Block]	'
	The following table summarizes the Company’s outstanding convertible promissory note obligations:
							Principal Balance Outstanding
	Issue Date	Maturity	Stated			Conversion Terms	December 31, 2013		December 31,
		Date	Interest						2012
			Rate
	6/5/13	12/2/13		6	%	Fixed at $0.02		20,000		-0-
	11/4/12	5/3/13		6	%	Fixed at $0.01		10,173		10,173
	8/23/12	2/19/13		6	%	Fixed at $0.015		50,000		50,000
	Nov-12	On Demand		None		Variable conversion price		720		720
	6/6/11	6/6/13		5	%	Fixed at $0.04		10,000		10,000
	4/11/11	4/11/13		5	%	Fixed at $0.04		25,000		25,000
	5/1/11	5/1/13		5	%	Fixed at $0.10		4,250		4,250
	4/1/11	4/1/13		5	%	Variable conversion price		4,250		4,250
	09/21/2012-09/01/2013	03/20/2013-06/05/2013		6	%	Fixed prices ranging from $0.0051-$0.0545				154,900
	12/28/10	On Demand		5	%	Fixed at $0.0030				13,000
	12/28/2010– 06/09/2011	12/6/11		5	%	Variable conversion price				375,000
	8/21/12	2/21/13		None		Variable conversion price				6,066
	12/13/10	12/13/12		5	%	Variable conversion price				100,000
	6/6/12	12/3/12		6	%	Fixed at $0.03				13,000
	9/26/11	3/24/12		6	%	Fixed at $0.10				3,000
	4/27/11	4/27/13		5	%	Variable conversion price		-0-		50,000
		Sub total						124,393		819,359
		Discount on convertible promissory notes						-0-		-50,467
		Current portion of convertible promissory notes, net					$	124,393	$	768,892

PREFERRED_STOCK_Tables

PREFERRED STOCK (Tables) (Warrant [Member])	12 Months Ended
	Dec. 31, 2013
Warrant [Member]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table summarizes the Company’s warrant activity for the year ended December 31, 2013.
		Number of Warrants		Weighted Average Exercise Price
	Outstanding as of December 31, 2011		1,392,251	$	0.07
	Issued in connection with convertible debt offerings		11,364,773		0.07
	Exercised		-146,694		0.17
	Expired		-25,501		0.01
	Outstanding as of December 31, 2012		12,584,829		0.04
	Issued in connection with convertible debt offerings		83,333,250		0.06
	Exercised		-		0
	Cancelled		-11,364,773		0.04
	Expired		-		0
	Outstanding as of December 31, 2013		84,553,306		0.06

STOCK_OPTION_PLAN_Tables

STOCK OPTION PLAN (Tables)	12 Months Ended
	Dec. 31, 2013
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	'
	Stock-based compensation expense for all plans for the years ended December 31, and 2013 and 2012, is classified in the statements of operations as follows:
		Year ended			Year ended
		December 31,			December 31,
		2013			2012
	Research and development	$	337,494		$	101,566
	General and administrative		406,195			282,038
	Total	$	743,689		$	383,604
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	'
	The fair value of the Company’s stock-based awards during the twelve months ended December 31, 2013 and 2012 were estimated using the following assumptions:
		Year Ended			Year Ended
		December 31,			December 31,
		2013			2012
	Weighted-average volatility	90	%		108	%
	Weighted-average expected term	5			5
	Expected dividends	0	%		0	%
	Risk-free investment rate	2	%		0.5	%
	Expected forfeiture rate	0	%		0	%
Stock Plan 2008 [Member]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table is a summary of activity under the Plan:
		Common stock options		Weighted Average		Outstanding Options
						Common
						Weighted Average Remaining
		outstanding		Exercise Price		Contractual Term
	Balance – December 31, 2011	9,206,247		0.02		6.4
	Options granted (weighted-average fair value of $0.
	Employee	—		—		—
	Non-Employee	—		—		—
	Options cancelled	—		—		—
	Options Exercised	-7,377,221		0.02		—
	Balance – December 31, 2012	1,829,026		0.02		6.4
	Options granted (weighted-average fair value of $0.52
	Employee	776,924		0.05		9.2
	Non-Employee	5,746,155		0.05		9.2
	Options cancelled	-1,210,817		—		—
	Options Exercised	—		—		—
	Balance – December 31, 2013	6,941,288		0.05		9
	Options vested December 31, 2013	6,891,288
Preferred Stock Plan 2012 [Member]	'
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	'
	The following table is a summary of activity under the Preferred Stock Plan:
		Preferred Stock Options		Weighted Average		Outstanding
						Preferred Options
						Weighted Average Remaining
		Outstanding		Exercise Price		Contractual Term
	Balance – December 31, 2011	—		—		—
	Preferred options granted (weighted-average fair value of $0.0237)
	Employee	2,287,500		0.4742		9.5
	Non-Employee	160,500		0.225		9.8
	Balance – December 31, 2012	2,448,000		0.4578		9.6
	Preferred options cancelled	-160,500		0.225		9.8
	Balance – December 31, 2013	2,287,500		0.4742		8.5
	Preferred options vested at December 31, 2012	1,318,359

INCOME_TAXES_Tables

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2013
Income Tax Disclosure [Abstract]	'
Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]	'
	The reported amount of income tax expense attributable to operations for the year differs from the amount that would result from applying domestic federal statutory tax rates to loss before income taxes from operations as summarized below:
	Income (Loss) before income taxes	Year ended			Year ended
		December 31, 2013			December 31, 2012
	United States	$	-15,130,681		$	-5,135,618
	Foreign		—			—
	Total Income (Loss) before income taxes	$	-15,130,681		$	-5,135,618
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	'
		Year ended December 31, 2013			Year ended December 31, 2012
	Federal tax expense (benefit) at statutory rate	$	-5,144,773		$	-1,746,110
	State tax expense (benefit) net of federal tax effect		-538,715			-298,348
	R&D Credit		-46,000			-19,994
	Non-deductible expenses		2,191,507			88,368
	Change in Valuation Allowance		3,537,981			1,976,084
	Other income		—			—
	Total tax expense	$	—		$	—
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
	The significant components of deferred tax assets are as follows:
		Year ended December 31, 2013			Year ended December 31, 2012
	Deferred tax assets:
	Net operating loss carry-forward	$	7,317,778		$	4,162,890
	Tax credit carry-forward		203,889			125,954
	Accrued liabilities		722,863			419,704
	Capitalized start-up costs		15,194			15,194
	Depreciation		1,351			1,351
	Gross Deferred Tax Assets		8,263,075			4,725,093
	Valuation Allowance		-8,263,075			-4,725,093
	Net deferred tax assets	$	—		$	—
		December 31, 2013				December 31, 2012
	Federal tax expense (benefit) at statutory rate		34	%			34	%
	State tax expense (benefit) net of federal tax effect		3.6	%			5.8	%
	R&D Credit		0.3	%			0.4	%
	Non-deductible expenses		-14.5	%			-1.7	%
	Change in Valuation Allowance		-23.4	%			-38.5	%
	Total tax expense		—	%			—	%
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	'
	It is the Company’s policy to include penalties and interest expense related to income taxes as a component of tax expense, as necessary.
	Beginning balance January 1, 2011	$	12,391
	Increase/(decrease) of unrecognized tax benefits taken in prior years		—
	Increase/(decrease) of unrecognized tax benefits related to current year		4,558
	Increase/(decrease) of unrecognized tax benefits related to settlements		—
	Reductions to unrecognized tax benefits related lapsing statute of limitations		—
	Ending balance at December 31, 2012	$	16,949
	Increase/(decrease) of unrecognized tax benefits taken in prior years
	Increase/(decrease) of unrecognized tax benefits related to current year		10,487
	Increase/(decrease) of unrecognized tax benefits related to settlements		—
	Reductions to unrecognized tax benefits related lapsing statute of limitations		—
	Ending balance at December 31, 2013	$	27,436

GENERAL_Details_Textual

GENERAL (Details Textual)	12 Months Ended
	Dec. 31, 2013
Nature Of Operations [Line Items]	'
Date of Incorporation	14-Jan-08
Date of Reincorporation	5-Apr-13

DEVELOPMENT_STAGE_AND_GOING_CO3

DEVELOPMENT STAGE AND GOING CONCERN (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Jan. 13, 2008	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013
								Scenario, Previously Reported [Member]	Scenario, Previously Reported [Member]	Scenario, Previously Reported [Member]	Restatement Adjustment [Member]	Restatement Adjustment [Member]	Restatement Adjustment [Member]
Restatement to Prior Year Balance Sheets [Line Items]	'	'	'	'	'	'	'	'	'	'	'	'	'
Derivative liabilities	$5,859,170	$26,893	'	'	'	'	'	$1,544,443	$250,011	$921,954	$2,427,367	$419,239	$794,468
Convertible promissory notes	124,393	768,892	'	'	'	'	'	485,936	674,161	328,727	475,780	631,961	328,726
Total Liabilities	8,539,190	4,737,753	'	'	'	'	'	4,664,706	5,576,483	6,165,888	5,537,474	5,703,511	6,038,401
Additional paid in capital	18,938,039	7,991,465	'	'	'	'	'	13,760,385	10,728,916	9,367,041	16,053,726	12,678,967	11.274893
Deficit accumulated during the development stage	'	'	'	'	'	'	'	-17,645,773	-15,620,221	-14,719,336	-20,737,511	-17,697,300	-16,499,701
Stockholderbs deficit	($7,519,170)	($3,527,816)	($3,349,944)	($1,534,645)	($1,074,711)	($768,521)	$0	($3,354,569)	($4,449,302)	($4,967,128)	($4,152,966)	($4,576,330)	($4,839,641)

DEVELOPMENT_STAGE_AND_GOING_CO4

DEVELOPMENT STAGE AND GOING CONCERN (Details 1) (USD $)	12 Months Ended						72 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended	3 Months Ended			6 Months Ended	9 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2013	Sep. 30, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Jun. 30, 2013	Sep. 30, 2013
								Scenario, Previously Reported [Member]	Scenario, Previously Reported [Member]	Scenario, Previously Reported [Member]	Scenario, Previously Reported [Member]	Scenario, Previously Reported [Member]	Restatement Adjustment [Member]	Restatement Adjustment [Member]	Restatement Adjustment [Member]	Restatement Adjustment [Member]	Restatement Adjustment [Member]
Restatement Of Prior Year Income [Line Items]	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'	'
Operating loss	($5,711,134)	($4,090,342)	'	'	'	'	($15,435,713)	($678,548)	($1,304,475)	($1,884,597)	($3,189,072)	($3,867,619)	($678,548)	($1,304,475)	($1,884,597)	($3,189,072)	($3,867,619)
Non-operating income (loss)	-9,420,547	-1,045,276	'	'	'	'	-11,192,145	-1,346,964	403,590	-972,691	-569,101	-1,916,066	-2,361,623	106,876	-2,753,056	-2,646,180	-5,007,804
Net loss	($15,131,681)	($5,135,618)	($4,440,103)	($1,207,561)	($306,190)	($406,706)	($26,627,858)	($2,025,512)	($900,885)	($2,857,288)	($3,758,173)	($5,783,685)	($3,040,171)	($1,197,599)	($4,637,653)	($5,835,252)	($8,875,423)
Net loss per common share, basic and diluted (in dollar per share)	($0.03)	($0.04)	'	'	'	'	'	$0	$0	($0.01)	($0.01)	($0.01)	($0.01)	$0	($0.01)	($0.01)	($0.02)

DEVELOPMENT_STAGE_AND_GOING_CO5

DEVELOPMENT STAGE AND GOING CONCERN (Details Textual) (USD $)	12 Months Ended						72 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2013
Development Stage Enterprises [Line Items]	'	'	'	'	'	'	'
Cash and cash equivalents	$1,032,634	$157,174	'	'	'	'	$1,032,634
Net loss	-15,131,681	-5,135,618	-4,440,103	-1,207,561	-306,190	-406,706	-26,627,858
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	-3,473,237	-1,154,126	'	'	'	'	-8,206,256
Deficit accumulated during the development stage	-27,032,131	-11,862,048	'	'	'	'	-27,032,131
Bonus, Total	443,874	'	'	'	'	'	'
Chief Executive Officer [Member]	'	'	'	'	'	'	'
Development Stage Enterprises [Line Items]	'	'	'	'	'	'	'
Bonus, Total	230,222	'	'	'	'	'	'
Chief Scientific Officer [Member]	'	'	'	'	'	'	'
Development Stage Enterprises [Line Items]	'	'	'	'	'	'	'
Bonus, Total	$213,763	'	'	'	'	'	'
Minimum [Member]	'	'	'	'	'	'	'
Development Stage Enterprises [Line Items]	'	'	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'10 years 10 months 24 days	'	'	'	'	'	'
Maximum [Member]	'	'	'	'	'	'	'
Development Stage Enterprises [Line Items]	'	'	'	'	'	'	'
Finite-Lived Intangible Asset, Useful Life	'18 years 6 months	'	'	'	'	'	'

BALANCE_SHEET_DETAILS_Details

BALANCE SHEET DETAILS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Balance Sheet Details [Line Items]	'	'
Prepaid Expense and Other Assets, Current	$215,186	$520,620
Accrued Liabilities, Current	292,395	18,746
Due to Related Parties, Current	247,967	243,525
Prepaid Expenses [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Prepaid Expense and Other Assets, Current	91,853	409,710
Deferred Financing Costs [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Prepaid Expense and Other Assets, Current	109,233	46,909
Other Current Assets [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Prepaid Expense and Other Assets, Current	14,100	64,001
Accrued Compensation And Related Benefits [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Accrued Liabilities, Current	266,407	18,746
Series D Convertible Preferred Dividend [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Accrued Liabilities, Current	25,987	0
Accrued Interest [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Due to Related Parties, Current	25,884	21,442
Promissory Notes Payable [Member]	'	'
Balance Sheet Details [Line Items]	'	'
Due to Related Parties, Current	$222,083	$222,083

BALANCE_SHEET_DETAILS_Details_

BALANCE SHEET DETAILS (Details Textual) (USD $)	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
			Promissory Notes Payable [Member]
Balance Sheet Details [Line Items]	'	'	'
Debt Instrument, Issuance Date	'	'	5-Mar-08
Debt Instrument, Maturity Date	'	'	5-Mar-15
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%	2.00%
Debt Instrument, Convertible, Conversion Price	'	'	$0.08
Conversion of Stock, Shares Converted	'	'	3,107,356

FAIR_VALUE_MEASUREMENTS_Detail

FAIR VALUE MEASUREMENTS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	$0	$232,988
Derivative Liability	5,859,170	26,893
Total fair value	5,859,170	259,881
Fair Value, Inputs, Level 1 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	0	0
Derivative Liability	0	0
Total fair value	0	0
Fair Value, Inputs, Level 2 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	0	0
Derivative Liability	0	0
Total fair value	0	0
Fair Value, Inputs, Level 3 [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Warrant liability	0	232,988
Derivative Liability	5,859,170	26,893
Total fair value	$5,859,170	$259,881

FAIR_VALUE_MEASUREMENTS_Detail1

FAIR VALUE MEASUREMENTS (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Balance	$259,881	$424,637
Conversion of warrants to common stock	'	-2,031
Issuance of convertible notes	8,582,295	4,044,349
Reclass to additional paid in capital	-2,711,816	'
Change in fair value	-271,190	-4,207,074
Balance	5,859,170	259,881
Warrant Liability [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Balance	232,988	283,931
Conversion of warrants to common stock	'	-2,031
Issuance of convertible notes	0	0
Reclass to additional paid in capital	0	'
Change in fair value	-232,988	-48,912
Balance	0	232,988
Derivative Liabilities [Member]	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'
Balance	26,893	140,706
Conversion of warrants to common stock	'	0
Issuance of convertible notes	8,582,295	4,044,349
Reclass to additional paid in capital	-2,711,816	'
Change in fair value	-38,202	-4,158,162
Balance	$5,859,170	$26,893

FAIR_VALUE_MEASUREMENTS_Detail2

FAIR VALUE MEASUREMENTS (Details 2)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Contractual life (years)	'4 months 24 days	'6 months
Expected dividends	0.00%	0.00%
Minimum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Annualized volatility	331.00%	275.00%
Risk-free investment rate	0.09%	0.01%
Maximum [Member]	'	'
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]	'	'
Annualized volatility	335.00%	624.00%
Risk-free investment rate	0.62%	0.12%

FAIR_VALUE_MEASUREMENTS_Detail3

FAIR VALUE MEASUREMENTS (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Derivative Fair Value Of Liabilities	$5,859,170	$259,881	$424,637
Derivative Financial Instrument Warrant Liabilities [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Derivative Fair Value Of Liabilities	0	232,988	283,931
Changes in fair value	232,988	48,912	'
Derivative Financial Instruments, Liabilities [Member]	'	'	'
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]	'	'	'
Derivative Fair Value Of Liabilities	5,859,170	26,893	140,706
Changes in fair value	$13,000	$436,095	'

NET_LOSS_PER_SHARE_Details

NET LOSS PER SHARE (Details) (USD $)	12 Months Ended								72 Months Ended
	Dec. 31, 2013		Dec. 31, 2012		Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2013
Numerator	'		'		'	'	'	'	'
Net Loss	($15,131,681)		($5,135,618)		($4,440,103)	($1,207,561)	($306,190)	($406,706)	($26,627,858)
Preferred stock dividend	38,402		0		'	'	'	'	38,402
Net loss applicable to common stockholders	($15,170,083)		($5,135,618)		'	'	'	'	($26,666,260)
Denominator	'		'		'	'	'	'	'
Common stock - basic (in shares)	450,931,510		140,710,454		'	'	'	'	'
Common shares equivalents (in shares)	0		0		'	'	'	'	'
Common stock - diluted (in shares)	450,931,510		140,710,454		'	'	'	'	'
Net loss per share (in dollars per share)	($0.03)		($0.04)		'	'	'	'	'
Potentially dilutive securities:	'		'		'	'	'	'	'
Outstanding time-based common stock options	6,941,000	[1]	0	[1],[2]	'	'	'	'	'
Outstanding time-based preferred stock options	2,288,000	[1]	0	[1],[2]	'	'	'	'	'
Warrants	84,553,000	[1]	0	[1],[2]	'	'	'	'	'
Relating party liabilities	3,107,000		0		'	'	'	'	'
Convertible securities	6,325,000	[1]	0	[1],[2]	'	'	'	'	'
Convertible preferred stock	753,000	[1],[3]	0	[1],[2],[3]	'	'	'	'	'
Senior Convertible Debentures 8 [Member]	'		'		'	'	'	'	'
Potentially dilutive securities:	'		'		'	'	'	'	'
Convertible securities	75,000,000		0		'	'	'	'	'
[1]	The impact of time-based stock options, warrants, the convertible notes and the convertible preferred stock on earnings per share is anti-dilutive in a period of loss from continuing operations.
[2]	Total anti dilutive securities in 2012 was approximately 84,000,000.
[3]	Includes Series C and D Convertible Preferred Stock.

NET_LOSS_PER_SHARE_Details_Tex

NET LOSS PER SHARE (Details Textual)	12 Months Ended
	Dec. 31, 2012
Net Income Loss [Line Items]	'
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	84,000,000

INTANGIBLE_ASSETS_Details

INTANGIBLE ASSETS (Details) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
Total intangible assets net	$611,094	$532,143
Power 3 Medical License [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total intangible assets net	430,252	484,643
Memory Dx LymPro License [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total intangible assets net	145,940	47,500
University of Massachusetts License [Member]	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Total intangible assets net	$34,902	$0

INTANGIBLE_ASSETS_Details_1

INTANGIBLE ASSETS (Details 1) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Amortizable Intangible Assets [Line Items]	'	'
Finite-Lived Intangible Assets, License costs, Gross Carrying Amount	$681,143	$532,143
Finite-Lived Intangible Assets, License costs, Accumulated Amortization	-70,049	0
Finite-Lived Intangible Assets, License costs, Net Book Value	$611,094	$532,143

INTANGIBLE_ASSETS_Details_2

INTANGIBLE ASSETS (Details 2) (USD $)	Dec. 31, 2013	Dec. 31, 2012
Finite-Lived Intangible Assets [Line Items]	'	'
2014	$44,599	'
2015	44,599	'
2016	44,721	'
2017	44,599	'
2018	44,599	'
thereafter	387,977	'
Total	$611,094	$532,143

INTANGIBLE_ASSETS_Details_Text

INTANGIBLE ASSETS (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013
University of Massachusetts License [Member]	'
Indefinite-lived Intangible Assets [Line Items]	'
License Agreement Upfront Fee	$35,000
Memory Dx, LLC [Member]	'
Indefinite-lived Intangible Assets [Line Items]	'
Stock Issued During Period, Shares, New Issues	2,000,000
Sale of Stock, Price Per Share	$0.04
Royalty Percentage	9.00%
Payment Made For Validation Study	50,000
Payment To Be Made On Completion Of Validation Study	$1,000,000

COLLABORATIVE_AGREEMENTS_Detai

COLLABORATIVE AGREEMENTS (Details Textual) (USD $)	12 Months Ended		72 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Collaborative Agreements, Royalty Percentage	2.00%	'	'
Research and development	$2,088,992	$583,869	$4,278,647
UMass Agreement [Member]	'	'	'
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]	'	'	'
Research and development	$34,441	'	'

CONVERTIBLE_NOTES_PAYABLE_Deta

CONVERTIBLE NOTES PAYABLE (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument, Redemption [Line Items]	'	'
Stated Interest Rate	8.00%	8.00%
Principal Balance Outstanding	$0	$740,000
Convertible Notes Payable Issuance One [Member]	'	'
Debt Instrument, Redemption [Line Items]	'	'
Issue Date	14-Nov-12	'
Maturity Date	3-Jun-13	'
Stated Interest Rate	10.00%	'
Conversion Terms	'Fixed at $0.10	'
Principal Balance Outstanding	0	600,000
Convertible Notes Payable Issuance Two [Member]	'	'
Debt Instrument, Redemption [Line Items]	'	'
Issue Date	4-Oct-11	'
Maturity Date	6-Sep-14	'
Stated Interest Rate	20.00%	'
Conversion Terms	'$0.05 subject to adjustments	'
Principal Balance Outstanding	$0	$140,000

CONVERTIBLE_NOTES_PAYABLE_Deta1

CONVERTIBLE NOTES PAYABLE (Details Textual) (Subsequent Event [Member])	12 Months Ended
	Dec. 31, 2013
Subsequent Event [Member]	'
Debt Instrument, Redemption [Line Items]	'
Stock Issued During Period, Shares, Conversion of Convertible Securities	93,860,000

8_SENIOR_CONVERTIBLE_DEBENTURE2

8% SENIOR CONVERTIBLE DEBENTURES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument, Redemption [Line Items]	'	'
Stated Interest Rate	8.00%	8.00%
Long-term Debt, Gross	$3,333,332	$0
Discount on convertible promissory notes	0	-50,467
Current portion of 8% convertible promissory notes, net	931,942	0
8% Senior Convertible Debenture Issuance One [Member]	'	'
Debt Instrument, Redemption [Line Items]	'	'
Issue Date	2-Oct-13	'
Maturity Date	2-Oct-14	'
Stated Interest Rate	8.00%	'
Conversion Terms	'Variable conversion price	'
Long-term Debt, Gross	1,788,889	0
8% Senior Convertible Debenture Issuance Two [Member]	'	'
Debt Instrument, Redemption [Line Items]	'	'
Issue Date	6-Sep-13	'
Maturity Date	6-Sep-14	'
Stated Interest Rate	8.00%	'
Conversion Terms	'Variable conversion price	'
Long-term Debt, Gross	1,544,443	0
8% Senior Convertible Debenture Issuance One And Two [Member]	'	'
Debt Instrument, Redemption [Line Items]	'	'
Discount on convertible promissory notes	-2,401,390	0
8% Senior Convertible Debentures [Member]	'	'
Debt Instrument, Redemption [Line Items]	'	'
Stated Interest Rate	8.00%	'
Current portion of 8% convertible promissory notes, net	$931,942	$0

CONVERTIBLE_PROMISSORY_NOTES_D

CONVERTIBLE PROMISSORY NOTES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Debt Instrument [Line Items]	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%
Long-term Debt, Gross	$3,333,332	$0
Debt Instrument, Unamortized Discount	0	-50,467
Convertible Promissory Notes Payable Current	124,393	768,892
Convertible Promissory Notes Payable Issuance One [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	5-Jun-13	'
Debt Instrument, Maturity Date	2-Dec-13	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.02	'
Long-term Debt, Gross	20,000	0
Convertible Promissory Notes Payable Issuance Two [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	4-Nov-12	'
Debt Instrument, Maturity Date	3-May-13	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.01	'
Long-term Debt, Gross	10,173	10,173
Convertible Promissory Notes Payable Issuance Three [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	23-Aug-12	'
Debt Instrument, Maturity Date	19-Feb-13	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.015	'
Long-term Debt, Gross	50,000	50,000
Convertible Promissory Notes Payable Issuance Four [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	1-Nov-12	'
Debt Instrument, Interest Rate, Stated Percentage	0.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Variable conversion price	'
Long-term Debt, Gross	720	720
Debt Instrument Maturity	'On Demand	'
Convertible Promissory Notes Payable Issuance Five [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	6-Jun-11	'
Debt Instrument, Maturity Date	6-Jun-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.04	'
Long-term Debt, Gross	10,000	10,000
Convertible Promissory Notes Payable Issuance Six [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	11-Apr-11	'
Debt Instrument, Maturity Date	11-Apr-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.04	'
Long-term Debt, Gross	25,000	25,000
Convertible Promissory Notes Payable Issuance Seven [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	1-May-11	'
Debt Instrument, Maturity Date	1-May-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.10	'
Long-term Debt, Gross	4,250	4,250
Convertible Promissory Notes Payable Issuance Eight [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	1-Apr-11	'
Debt Instrument, Maturity Date	1-Apr-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Variable conversion price	'
Long-term Debt, Gross	4,250	4,250
Convertible Promissory Notes Payable Issuance Nine [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	21-Sep-12	'
Debt Instrument, Maturity Date	20-Mar-13	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed prices ranging from $0.0051-$0.0545	'
Long-term Debt, Gross	'	154,900
Debt Instrument Issuance Date2	1-Sep-13	'
Debt Instrument Maturity Date1	5-Jun-13	'
Convertible Promissory Notes Payable Issuance Ten [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	28-Dec-10	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.0030	'
Long-term Debt, Gross	'	13,000
Debt Instrument Maturity	'On Demand	'
Convertible Promissory Notes Payable Issuance Eleven [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	28-Dec-10	'
Debt Instrument, Maturity Date	6-Dec-11	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Variable conversion price	'
Long-term Debt, Gross	'	375,000
Debt Instrument Issuance Date2	9-Jun-11	'
Convertible Promissory Notes Payable Issuance Twelve [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	21-Aug-12	'
Debt Instrument, Maturity Date	21-Feb-13	'
Debt Instrument, Interest Rate, Stated Percentage	0.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Variable conversion price	'
Long-term Debt, Gross	'	6,066
Convertible Promissory Notes Payable Issuance Thirteen [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	13-Dec-10	'
Debt Instrument, Maturity Date	13-Dec-12	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Variable conversion price	'
Long-term Debt, Gross	'	100,000
Convertible Promissory Notes Payable Issuance Fourteen [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	6-Jun-12	'
Debt Instrument, Maturity Date	3-Dec-12	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.03	'
Long-term Debt, Gross	'	13,000
Convertible Promissory Notes Payable Issuance Fifteen [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	26-Sep-11	'
Debt Instrument, Maturity Date	24-Mar-12	'
Debt Instrument, Interest Rate, Stated Percentage	6.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Fixed at $0.10	'
Long-term Debt, Gross	'	3,000
Convertible Promissory Notes Payable Issuance Sixteen [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt Instrument, Issuance Date	27-Apr-11	'
Debt Instrument, Maturity Date	27-Apr-13	'
Debt Instrument, Interest Rate, Stated Percentage	5.00%	'
Debt Instrument, Convertible, Terms of Conversion Feature	'Variable conversion price	'
Long-term Debt, Gross	0	50,000
Convertible Promissory Notes Payable Issuance One To Sixteen [Member]	'	'
Debt Instrument [Line Items]	'	'
Long-term Debt, Gross	$124,393	$819,359

CONVERTIBLE_PROMISSORY_NOTES_D1

CONVERTIBLE PROMISSORY NOTES (Details Textual) (USD $)	12 Months Ended		1 Months Ended	12 Months Ended	1 Months Ended	12 Months Ended			1 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Jan. 30, 2013	Dec. 31, 2012	Jul. 31, 2013	Dec. 31, 2013	Dec. 31, 2013	Aug. 19, 2013	Jan. 30, 2013	Jan. 30, 2013
			Dominion Note [Member]	Dominion Note [Member]	Restructuring Of Convertible Debentures and Related Warrants [Member]	Restructuring Of Convertible Debentures and Related Warrants [Member]	Restructuring Of Convertible Debentures and Related Warrants [Member]	Series D Convertible Preferred Stock	Maximum	Minimum
							Dominion Capital, LLC. [Member]		Dominion Note [Member]	Dominion Note [Member]
Debt Instrument [Line Items]	'	'	'	'	'	'	'	'	'	'
Debt Instrument, Convertible, Conversion Price	'	'	$0.10	'	'	$0.03	'	$0.03	'	'
Debt Conversion, Converted Instrument, Shares Issued	98,456,000	'	'	'	12,500,000	'	'	'	'	'
Proceeds from Convertible Debt	'	'	$250,000	$600,000	'	'	'	'	'	'
Extinguishment of Debt, Amount	3,463,162	'	'	'	'	'	'	'	'	'
Debt Instrument, Debt Default, Amount	124,000	'	'	'	'	375,000	'	'	'	'
Debt Instrument, Maturity Date	'	'	28-Oct-13	'	'	'	'	'	'	'
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%	10.00%	'	'	'	'	8.00%	'	'
Convertible Promissory Notes Payable Current	124,393	768,892	'	'	'	187,500	375,000	'	2,000,000	600,000
Cashless Warrants Amount	'	'	'	'	'	500,000	'	'	'	'
Payments Made To Acquire Promissory Notes	'	'	'	'	'	'	562,500	'	'	'
Warrants Retired Amount	'	'	'	'	'	'	37,500	'	'	'
Floorless Discount, Percentage	'	'	'	'	'	66.60%	'	'	'	'
Debt Conversion Convertible Instrument Amount One	'	'	'	'	'	900,000	'	'	'	'
Debt Conversion, Convertible Instrument, Shares Issuable One	'	'	'	'	'	27,000,000	'	'	'	'
Debt Instrument Convertible Conversion Price Two	'	'	'	'	'	$0.02	'	'	'	'
Debt Conversion, Convertible Instrument, Shares Issuable Two	'	'	'	'	'	25,000,000	'	'	'	'
Debt Conversion Convertible Instrument Amount Three	'	'	'	'	'	187,500	'	'	'	'
Debt Instrument Convertible Conversion Price Three	'	'	'	'	'	$0.02	'	'	'	'
Extended Amortization Schedule Payments Provided Amount	'	'	'	'	'	'	'	'	250,000	200,000
Debt Conversion Convertible Instrument Amount Two	'	'	'	'	'	375,000	'	'	'	'
Debt Conversion, Converted Instrument, Amount	'	'	'	'	$187,500	'	'	'	'	'

COMMITMENTS_AND_CONTINGENCIES_

COMMITMENTS AND CONTINGENCIES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Loss Contingencies [Line Items]	'	'
Lease Agreement Term	'one-year	'
Lease Agreement Initiation Period	'October 2013	'
Lease Rental Payments, Per Month	$6,700	'
Operating Leases, Rent Expense	29,511	33,596
Loss Contingency, Settlement Agreement, Date	'	'August 2012
Litigation Settlement, Amount	'	44,000
Litigation Settlement Amount, In Monthly Installments	'	$5,000

PREFERRED_STOCK_Details

PREFERRED STOCK (Details) (Warrant [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Warrant [Member]	'	'
Share Based Compensation Stock Options Activities [Line Items]	'	'
Option Outstanding - Balance	12,584,829	1,392,251
Number of Shares - Issued in connection with convertible debt offerings	83,333,250	11,364,773
Common Stock Option Outstanding - Options Exercised	0	-146,694
Common Stock Option Outstanding - Options Cancelled	-11,364,773	'
Number of Shares - Expired	0	-25,501
Option Outstanding - Balance	84,553,306	12,584,829
Weighted Average Exercise Price - Balance	$0.04	$0.07
Weighted Average Exercise Price - Issued in connection with convertible debt offerings	$0.06	$0.07
Weighted Average Exercise Price - Exercised	$0	$0.17
Weighted Average Exercise Price - Cancelled	$0.04	'
Weighted Average Exercise Price - Expired	$0	$0.01
Weighted Average Exercise Price - Balance	$0.06	$0.04

PREFERRED_STOCK_Details_Textua

PREFERRED STOCK (Details Textual) (USD $)

12 Months Ended

0 Months Ended

12 Months Ended

1 Months Ended

12 Months Ended

1 Months Ended

1 Months Ended

12 Months Ended

Dec. 31, 2013

Dec. 31, 2012

Mar. 07, 2014

Mar. 07, 2014

Mar. 07, 2014

Mar. 07, 2014

Dec. 31, 2013

31-May-12

Dec. 31, 2013

Dec. 31, 2012

Apr. 30, 2013

Dec. 31, 2013

Dec. 31, 2012

Aug. 19, 2013

Dec. 31, 2013

Dec. 31, 2012

Original Warrants [Member]

New Warrants [Member]

Subsequent Event [Member]

Subsequent Event [Member]

Debenture And Warrant Transaction [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series A Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series C Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Series D Convertible Preferred Stock [Member]

Original Warrants [Member]

New Warrants [Member]

Class of Stock [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Preferred Stock, Shareholders Entitled To Receive Stated Value, Per Share

'

'

'

'

'

'

'

$1

'

'

'

'

'

'

'

'

Conversion of Stock, Description

'

'

'

'

'

'

'

'The series A shares are convertible into the Companys common stock at a stated conversion price that is equal to the lessor of 1) 110% of the closing common stock price on the date of conversion or 2) 80% of the lowest closing common stock price occurring during a 30 trading day period prior to notice of conversion.

'

'

'

'

'

'

'

'

Stock Issued During Period, Value, Conversion of Convertible Securities

'

'

'

'

'

'

'

'

'

'

$750,000

'

'

'

'

'

Common Stock, Voting Rights

'

'

'

'

'

'

'

'

'

'

'The holders of Series C shares are entitled to 300 common stock equivalent votes per share on all corporate matters except those that by law only require a single series vote.

'

'

'

'

'

Stock Issued During Period, Value, Conversion of Convertible Securities, Net of Adjustments, Total

1,559,195

'

'

'

'

'

'

'

'

'

'

'

'

1,250,000

'

'

Preferred Stock Shares, Designated

'

'

'

'

'

'

'

'

250,000

250,000

'

750,000

750,000

1,300

1,300

1,300

Preferred Stock, Par or Stated Value Per Share

'

'

'

'

'

'

'

'

$0.00

$0.00

'

$0.00

$0.00

$1,000

$1,000

$1,000

Debt Instrument, Interest Rate, Stated Percentage

8.00%

8.00%

'

'

'

'

'

'

'

'

'

'

'

8.00%

'

'

Debt Instrument, Convertible, Conversion Price

'

'

'

'

'

'

'

'

'

'

'

'

'

$0.03

'

'

Preferred Stock, Conversion Basis

'

'

'

'

'

'

'

'

'

'

'

'

'

'The conversion price for the Series D Preferred Stock shall equal $0.03 per share, subject to adjustment; provided, however , in the event that during any period that the Series D Preferred Stock is outstanding, a holder delivers a conversion notice within 5 trading days following a period that the average of 5 consecutive Volume Weighted Average Prices (VWAPs) is less than $0.02, the conversion price shall be thereafter reduced, and only reduced, to equal the lesser of the then conversion price and 75% of the average of the lowest 5 consecutive VWAPs prior to the delivery of such conversion notice.

'

'

Warrants Issued To Purchase Common Stock, Shares

'

'

'

'

'

'

83,333,251

'

'

'

'

'

'

'

'

'

Warrants Exercise Price, Per Share

'

'

'

'

'

'

$0.06

'

'

'

'

'

'

'

'

'

Warrants Exercisable Term

'

'

'

'

'

'

'3 years

'

'

'

'

'

'

'

'

'

Warrants Exercise Price, Per Share, Based On Conditions

'

'

'

'

'

'

$0.00

'

'

'

'

'

'

'

'

'

Convertible Preferred Stock Shares Converted To Common Stock

'

'

'

'

'

'

'

'

8,094,117

'

'

'

'

'

'

'

Convertible Preferred Stock, Shares Issued upon Conversion

'

'

'

'

'

'

'

'

250,000

'

'

'

'

'

'

'

Preferred Stock, Redemption Terms

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'The redemption amount upon any triggering event is equal to the greater of 1) 130% of the stated value or 2) the stated value divided by the then conversion price multiplied by the VMAP on the trading day immediately preceding the triggering event, plus any accrued and unpaid dividends.

'

Adjustments to Additional Paid in Capital, Warrant Issued

'

'

'

'

60,000,000

'

'

'

'

'

'

'

'

'

'

'

Proceeds from Warrant Exercises

'

'

'

'

$3,600,000

'

'

'

'

'

'

'

'

'

'

'

Warrants To Purchase Of Common Stock Price Per Share

'

'

'

'

$0.06

'

'

'

'

'

'

'

'

'

'

'

Class of Warrant or Right, Exercise Price of Warrants or Rights

'

'

'

'

'

0.12

'

'

'

'

'

'

'

'

'

'

Warrants Term

'

'

'

'

'

'5 years

'

'

'

'

'

'

'

'

'

'

Common Stock Warrants Closing Price Per Share

'

'

'

'

'

$0.18

'

'

'

'

'

'

'

'

'

'

Warrants To Purchase Of Common Stock Shares

'

'

'

'

'

45,000,000

'

'

'

'

'

'

'

'

'

'

Warrant To Purchase Of Common Stock Exercised Description

'

'

'every four (4) Original Warrants

'purchase three (3) shares of common stock

'

'

'

'

'

'

'

'

'

'

'

'

COMMON_STOCK_Details_Textual

COMMON STOCK (Details Textual) (USD $)	12 Months Ended			15 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2013	Feb. 01, 2013
			Senior Convertible Debentures 8 [Member]	Depository Trust Company [Member]
Common Stock [Line Items]	'	'	'	'
Common Stock, Shares Authorized	1,000,000,000	1,000,000,000	'	'
Common Stock, Par or Stated Value Per Share	$0.00	$0.00	'	'
Common Stock, Shares Registration	173,333,160	'	'	'
Securities Deposit Number	'	'	'	234,841,928
Debt Instrument, Interest Rate, Stated Percentage	8.00%	8.00%	8.00%	'

STOCK_OPTION_PLAN_Details

STOCK OPTION PLAN (Details) (2008 Stock Plan [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
2008 Stock Plan [Member]	'	'	'
Share-based Compensation, Stock Options, Activity [Line Items]	'	'	'
Option Outstanding - Balance	1,829,026	9,206,247	'
Common Stock Option Outstanding - Options granted Employees	776,924	0	'
Common Stock Option Outstanding - Options granted Non-Employee	5,746,155	0	'
Common Stock Option Outstanding - Options Cancelled	-1,210,817	0	'
Common Stock Option Outstanding - Options Exercised	0	-7,377,221	'
Option Outstanding - Balance	6,941,288	1,829,026	9,206,247
Common Stock Option Outstanding - Options Vested	6,891,288	'	'
Weighted Average Exercise Price - Balance	$0.02	$0.02	'
Weighted Average Exercise Price - Options granted Employee	$0.05	$0	'
Weighted Average Exercise Price - Options granted Non-Employee	$0.05	$0	'
Weighted Average Exercise Price - Options cancelled	$0	$0	'
Weighted Average Exercise Price - Options Exercised	$0	$0.02	'
Weighted Average Exercise Price - Balance	$0.05	$0.02	$0.02
Outstanding Options Common Weighted Average Remaining Contractual Term - Employee	'9 years 2 months 12 days	'	'
Outstanding Options Common Weighted Average Remaining Contractual Term - Non-Employee	'9 years 2 months 12 days	'	'
Outstanding Options Common Weighted Average Remaining Contractual Term - Balance	'9 years	'6 years 4 months 24 days	'6 years 4 months 24 days

STOCK_OPTION_PLAN_Details_1

STOCK OPTION PLAN (Details 1) (2012 Preferred Stock Plan [Member], USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2011
2012 Preferred Stock Plan [Member]	'	'	'
Share-based Compensation, Stock Options, Activity [Line Items]	'	'	'
Option Outstanding - Balance	2,448,000	0	'
Preferred Stock Option Outstanding - Preferred options cancelled	-160,500	'	'
Preferred Stock Option Outstanding - Options granted Employees	'	2,287,500	'
Preferred Stock Option Outstanding - Options granted Non-Employee	'	160,500	'
Option Outstanding - Balance	2,287,500	2,448,000	0
Preferred options vested	'	1,318,359	'
Weighted Average Exercise Price - Balance	$0.46	$0	'
Weighted Average Exercise Price - Preferred options cancelled	$0.23	'	'
Weighted Average Exercise Price - Options granted Employee	'	$0.47	'
Weighted Average Exercise Price - Options granted Non-Employee	'	$0.23	'
Weighted Average Exercise Price - Balance	$0.47	$0.46	$0
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Preferred options cancelled	'9 years 9 months 18 days	'	'
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Options granted Employee	'	'9 years 6 months	'
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Options granted Non-Employee	'	'9 years 9 months 18 days	'
Outstanding Preferred Options Weighted Average Remaining Contractual Term - Balance	'8 years 6 months	'9 years 7 months 6 days	'0 years

STOCK_OPTION_PLAN_Details_2

STOCK OPTION PLAN (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	$743,689	$383,604
Research and Development Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	337,494	101,566
General and Administrative Expense [Member]	'	'
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]	'	'
Allocated Share-based Compensation Expense	$406,195	$282,038

STOCK_OPTION_PLAN_Details_3

STOCK OPTION PLAN (Details 3)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Share-based Payment Award, Stock Options, Valuation Assumptions [Line Items]	'	'
Weighted-average volatility	90.00%	108.00%
Weighted-average expected term	'5 years	'5 years
Expected dividends	0.00%	0.00%
Risk-free investment rate	2.00%	0.50%
Expected forfeiture rate	0.00%	0.00%

STOCK_OPTION_PLAN_Details_Text

STOCK OPTION PLAN (Details Textual) (USD $)	1 Months Ended	0 Months Ended	12 Months Ended
	Nov. 30, 2012	Jul. 15, 2012	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	'	'	$443,849	'
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	'	'	'2 years	'
Stock Plan 2008 [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	'	'	28,242,127	'
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	'	'	'10 years	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'4 years	'
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	'	'	$0.52	$0
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	623,618	'
Preferred Stock Plan 2012 [Member]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]	'	'	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	1,200,000	1,248,000	'	'
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	'	'	'	'4 years
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	'	'	$0.02	$0.02
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant	'	'	712,500	'

INCOME_TAXES_Details

INCOME TAXES (Details) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]	'	'
United States	($15,130,681)	($5,135,618)
Foreign	0	0
Total Income (Loss) before income taxes	($15,130,681)	($5,135,618)

INCOME_TAXES_Details_1

INCOME TAXES (Details 1) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Effective Income Tax Rate Reconciliation [Line Items]	'	'
Federal tax expense (benefit) at statutory rate	($5,144,773)	($1,746,110)
State tax expense (benefit) net of federal tax effect	-538,715	-298,348
R&D Credit	-46,000	-19,994
Non-deductible expenses	2,191,507	88,368
Change in Valuation Allowance	3,537,981	1,976,084
Other income	0	0
Total tax expense	$0	$0

INCOME_TAXES_Details_2

INCOME TAXES (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Deferred tax assets:	'	'
Net operating loss carry-forward	$7,317,778	$4,162,890
Tax credit carry-forward	203,889	125,954
Accrued liabilities	722,863	419,704
Capitalized start-up costs	15,194	15,194
Depreciation	1,351	1,351
Gross Deferred Tax Assets	8,263,075	4,725,093
Valuation Allowance	-8,263,075	-4,725,093
Net deferred tax assets	$0	$0
Federal tax expense (benefit) at statutory rate, Percentage	34.00%	34.00%
State tax expense (benefit) net of federal tax effect, Percentage	3.60%	5.80%
R&D Credit, Percentage	0.30%	0.40%
Non-deductible expenses, Percentage	-14.50%	-1.70%
Change in Valuation Allowance, Percentage	-23.40%	-38.50%
Total tax expense, Percentage	0.00%	0.00%

INCOME_TAXES_Details_3

INCOME TAXES (Details 3) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Unrecognized Tax Benefits Roll Forward [Line Items]	'	'
Beginning balance	$16,949	$12,391
Increase/(decrease) of unrecognized tax benefits taken in prior years	'	'
Increase/(decrease) of unrecognized tax benefits related to current year	10,487	4,558
Increase/(decrease) of unrecognized tax benefits related to settlements	0	'
Reductions to unrecognized tax benefits related lapsing statute of limitations	0	0
Ending balance	$27,436	$16,949

INCOME_TAXES_Details_Textual

INCOME TAXES (Details Textual) (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Line Items]	'	'
Valuation Allowance, Deferred Tax Asset, Change in Amount	$3,537,982	$1,976,084
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	0	'
Domestic Tax Authority [Member]	'	'
Income Tax Disclosure [Line Items]	'	'
Operating Loss Carryforwards	18,374,939	'
Operating Loss Carryforwards Expiration Period	'beginning in 2028	'
State and Local Jurisdiction [Member]	'	'
Income Tax Disclosure [Line Items]	'	'
Operating Loss Carryforwards	18,378,914	'
Operating Loss Carryforwards Expiration Period	'beginning in 2028	'
Domestic Research And Development Credit Carry-Forwards [Member]	'	'
Income Tax Disclosure [Line Items]	'	'
Tax Credit Carryforward, Amount	133,716	'
Tax Credit Carryforward Expiration Period	'beginning in 2029	'
State And Local Research And Development Credit Carry-Forwards [Member]	'	'
Income Tax Disclosure [Line Items]	'	'
Tax Credit Carryforward, Amount	$140,649	'
Tax Credit Carryforward Expiration Period	'beginning in 2029	'

RELATEDPARTY_TRANSACTIONS_Deta

RELATED-PARTY TRANSACTIONS (Details Textual) (USD $)

Dec. 31, 2013

Dec. 31, 2012

Oct. 31, 2010

Dec. 31, 2008

Dec. 31, 2007

Dec. 31, 2013

Dec. 31, 2012

Jul. 31, 2012

Dec. 31, 2013

Dec. 31, 2012

Dec. 31, 2013

31-May-12

Mar. 31, 2012

Mar. 31, 2012

Jan. 31, 2013

Dec. 31, 2013

Oct. 31, 2013

Acquisition Of MANF [Member]

Acquisition Of MANF [Member]

Acquisition Of MANF [Member]

Acquisition Of MANF [Member]

Acquisition Of MANF [Member]

Former Chairman [Member]

Former Chairman [Member]

Former Chairman [Member]

Former Chairman [Member]

Related Party Capital Transactions [Member]

Related Party Capital Transactions [Member]

Related Party Capital Transactions [Member]

Related Party Capital Transactions [Member]

Related Party Capital Transactions [Member]

Related Party Debt Transactions [Member]

8% Senior Convertible Debentures [Member]

Convertible Promissory Notes Issued One [Member]

Convertible Promissory Notes Issued Two [Member]

Convertible Promissory Notes Issued Three [Member]

Convertible Promissory Notes Issued Three [Member]

Related Party Transaction [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Funding EMS received to purchase intellectual property rights

'

'

'

'

$59,000

'

'

'

'

'

'

'

'

'

'

'

'

Funding Neurotrophics received to purchase intellectual property rights

'

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

Funding CNS received to purchase intellectual property rights

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes issued pursuant to investments made into Neurotrophics

'

'

'

100,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Installment payments made by CNS to EMS

'

'

'

95,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Notes issued pursuant to investments in favor of Neurotrophics, amount

'

'

'

'

'

0

0

'

'

'

'

'

'

'

'

'

'

Royalty from Commercial Revenue

'

'

2.50%

'

'

'

'

2.50%

'

'

'

'

'

'

'

'

'

Royalty from Commercial Revenue to John Commissiong

'

'

1.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty from Commercial Revenue to Gerald Commissiong

'

'

1.25%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Royalty from gross proceeds of the company to Martin D. Cleary

'

'

'

'

'

'

'

5.00%

'

'

'

'

'

'

'

'

'

Consulting services

'

'

'

'

'

'

'

'

0

0

479,166

'

'

'

'

'

'

Convertible Promissory Note converted, amount

'

'

'

'

'

'

'

'

'

'

'

5,556

21,000

30,000

100,000

60,172

'

Convertible Promissory Note converted, shares

'

'

'

'

'

'

'

'

'

'

'

'

217,280

608,300

2,765,625

'

'

Related Parties, Invested Amount

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5,000

Debenture And Warrants Aggregate Purchase Price

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

15,000

Debt Instrument Carrying Amount

$3,333,332

$0

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$5,556

Warrants Issued To Purchase Common Stock, Shares

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

138,889

SUBSEQUENT_EVENTS_Details_Text

SUBSEQUENT EVENTS (Details Textual) (Subsequent Event [Member], USD $)	0 Months Ended				1 Months Ended	0 Months Ended
	Mar. 12, 2014	Jan. 14, 2014	Jan. 14, 2014	Jan. 14, 2014	Feb. 28, 2014	Mar. 07, 2014
	Demand Promissory Note [Member]	Eltoprazine In-License Agreement [Member]	Service Agreement [Member]	Securities Purchase Agreement [Member]	Option Agreement [Member]	Purchase Agreement [Member]
		PGI Drug Discovery, LLC [Member]	PGI Drug Discovery, LLC [Member]	PGI Drug Discovery, LLC [Member]	University of Massachusetts [Member]	Lincoln Park Capital Fund, LLC [Member]
Subsequent Event [Line Items]	'	'	'	'	'	'
License Agreement Date Of Agreement	'	14-Jan-14	'	'	'	'
Payment Of License Agreement Cost	'	$100,000	'	'	'	'
Payment Of License Agreement Milestone Development Cost	'	4,000,000	'	'	'	'
Payment For Clinical Trials	'	650,000	'	'	'	'
Payment Of License Agreement Inventory Cost	'	500,000	'	'	'	'
Contractual Obligation, Total	'	'	450,000	'	'	'
Contractual Obligation, Future Minimum Payments Due, Remainder of Fiscal Year	'	'	150,000	'	'	'
Service Agreement Term	'	'	'3 years	'	'	'
Subscriptions Of Common Stock Shares	'	'	'	4,000,000	'	'
Subscriptions Of Common Stock Shares Granted Period	'	'	'	4,000,000	'	'
Option Agreement, Date Of Agreement	'	'	'	'	28-Feb-14	'
Option Agreement, Option Term	'	'	'	'	'18 months	'
Payment For Option Fees	'	'	'	'	1,000	'
Payment For Option Retainer Fees	'	'	'	'	15,000	'
Purchase Agreement Date	'	'	'	'	'	7-Mar-14
Purchase Obligation, Total	'	'	'	'	'	20,000,000
Purchase Of Common Stock, Shares	'	'	'	'	'	4,000,000
Purchase Of Common Stock,Value	'	'	'	'	'	400,000
Purchase Agreement Term	'	'	'	'	'	'30 months
Additional Paid in Capital, Common Stock	'	'	'	'	'	19,600,000
Purchase Agreement Amount	'	'	'	'	'	20,000,000
Stock Issued During Period, Shares, New Issues	'	'	'	'	'	6,000,000
Stock Issued During Period Additional Shares Issues	'	'	'	'	'	3,500,000
Percentage Of Investors Subscription Amount	'	'	'	'	'	2.00%
Promissory Note Payable Opted To Extend Maturity Date	12-Mar-14	'	'	'	'	'
Proceeds from Issuance or Sale of Equity, Total	'	'	'	'	'	500,000
Notes Issued	$500,000	'	'	'	'	'